

Recommendations from the ICM-VTE: Spine

The ICM-VTE Spine Delegates*

1 - Is routine screening for DVT required in the pre-operative and/or post-operative period for patients undergoing spine procedures?

Response/Recommendation: There is no role for routine screening for deep venous thrombosis (DVT) in patients undergoing spine procedures. Doppler ultrasonography surveillance may be considered in high-risk surgical patients including those who are older, with spine injury, personal history of VTE, malignancy, cervical spondylotic myelopathy (CSM), and/or non-ambulatory.

Strength of Recommendation: Limited.

Delegates vote: Agree 96.43% Disagree 3.57% Abstain 0.00% (Strong Consensus).

Rationale: Venous thromboembolism (VTE) is a well-known complication of major orthopaedic and spine surgeries. The reported incidence of VTE in patients undergoing spine surgery range from 0.29% – 31%¹⁻³. Moreover, the overall rates of pulmonary (PE) and associated fatality after spinal surgery are 1.38% and 0.34%, respectively²⁻⁵.

Although contrast venography has been used for diagnosis of DVT, it is not suitable for the routine screening of asymptomatic patients due to potential complications, technical issues, expense, and invasiveness⁶. Similarly, the use of D-dimer, a byproduct of fibrinolysis⁷, as a screening tool lacked sensitivity and specificity in detecting VTE after hip arthroplasty⁸⁻¹². Ultrasonography, on the other hand, has become the primary non-invasive method for investigating suspected DVT of the femoral and popliteal veins⁹. Standard ultrasound showed relatively high sensitivity (> 90%) for proximal or (around 60%) for below-the-knee DVT in a systematic review of diagnostic cohort studies¹³. Duplex ultrasonography (DUS) has also improved precision and efficiency in diagnosing DVT compared to most non-invasive techniques¹⁴. Furthermore, combined D-dimer and ultrasound screening in patients with acute spinal cord injury have improved the detection of VTE compared to D-dimer screening alone¹⁵.

However, controversy remains regarding the use of routine screening for DVT in the perioperative period for patients undergoing spine procedures. We performed an extensive

systematic review of all publications. A total of 26 articles that satisfied all inclusion criteria were selected for data extraction after full review. Information about these studies with respect to year of publication, level of evidence, number of patients, methods of screening, timing of screening, methods of prophylaxis, and incidence of VTE are summarized in Table I. Studies suggest against screening for patients undergoing spine surgery while others recognize that only patients at high risk may benefit. Based on the available literature, the risk factors for an increased risk of VTE in patients undergoing spine surgery may be seen in older patients, long periods of bedrest from paralysis and pain, high D-dimer level, longer duration of operation, intra-operative blood loss and transfusion, previous history of VTE, fracture, comorbid disease burden and tumor surgery¹⁶⁻⁴⁴. Studies reporting DVT and/or PE rates vary in the type of surgery included and the methods used to detect DVT ranging from clinical examination^{28,29} to screening DUS^{3,22,24-27,30-32,35,38-40,43,44}, screening enhanced computer tomography (CT)³⁴, D-dimer testing combined with DUS and/or enhanced CT^{18,33,36,37,41,42}, and venography⁵.

Five articles recommended preoperative and/or postoperative routine screening for DVT. Liu et al., investigated routine DVT screening in a retrospective cross-sectional study⁴⁰. Of 396 patients with CSM, 16 (4%) had preoperative DVT. They concluded that preoperative screening should be considered for patients with CSM, and in particular those who are older, have had longer duration of CSM, have poor lower limb mobility, and have a heart disease history. Oda et al., evaluated DVT occurrence after posterior spinal surgery⁵. Neither mechanical methods nor anticoagulation medications were used for prophylaxis against VTE in their cohort. Bilateral ascending venography was performed within 14 days after surgery. There were no patients with clinical signs of DVT and PE. However, 17 patients (15.5%) showed venographic evidence of DVT, of whom 16 had distal thrombi, and only one had a proximal thrombus. They suggested that the prevalence of DVT after posterior spinal surgery is higher than generally recognized. Ikeda et al., examined predictable factors of DVT after spine surgery. Postoperative DVT was detected using DUS¹⁸. Age, sex, body mass index (BMI), operation

*A list of the ICM-VTE Spine Delegates is included in a note at the end of the article.

Disclosure: The **Disclosure of Potential Conflicts of Interest** forms are provided with the online version of the article (<http://links.lww.com/JBJS/G863>).

TABLE I Summary of the 26 articles selected for inclusion in the review*

First author	Year	Level of Evidence	No cases	Methods of screening	Timing	Prophylaxis	Incidence of VTE
Ferree et al ²²	1993	Level IV	87	DUS	Within 2 weeks; 2-7 days after surgery	CS	6% DVT
Napolitano et al ²³	1995	Level IV	458	DUS	Biweekly	Heparin + PCD	10% DVT
Wood et al ²⁴	1997	Level II	134	DUS	5 and 7 days after surgery	Mixed	1.5% VTE
Dearborn et al ²⁵	1999	Level IV	318	DUS and CT	3-20 days after surgery	CS + PCD	2.2% symptomatic PE; 0.9% asymptomatic DVT
Oda et al ⁵	2000	Level III	110	Bilateral ascending venography	Within 14 days after surgery	None	15.5% DVT
Lee et al ²⁶	2000	Level IV	313	DUS	5 and 7 days after surgery	None	0.3% symptomatic DVT
Leon et al ³	2005	Level IV	74	DUS	weekly	Inferior vena cava filters in high-risk patients	1.3% PE
Epstein et al ²⁷	2006	Level IV	139	DUS	2 days after surgery	CS	2.8% DVT and 0.7% PE
Platzer et al ²⁸	2006	Level IV	978	Clinical	-	Mixed	2.2% VTE
Schizas et al ²⁹	2008	Level IV	270	Clinical and eCT	When clinical suspicion of PE	CS and chemical	2.2% symptomatic PE
Strowell et al ³⁰	2009	Level III	680	DUS	4 days after surgery	Standard care vs chemical (Epoetin Alfa)	4.7% in the epoetin alfa group and 2.1% in the standard care group
Kaabachi et al ³¹	2010	Level IV	40	DUS	Before surgery and 3, 7, 15 days after surgery	None	None
Epstein et al ³²	2011	Level IV	240	DUS, clinical and eCT	1 to 2 days after surgery	CS	3.6-6.7% PE (US negative)
Yoshikawa et al ³³	2011	Level IV	88	DD combined with eCT	Before and 1, 4, 7, 10, and 14 days after surgery	CS and PCD	5.7% DVT
Kim et al ³⁴	2011	Level IV	130	eCT	NR	CS	25.4% PE only, 3.8% PE and DVT, 2.3% DVT only
Al-Djalili et al ³⁵	2012	Level IV	158	Clinical + DUS	2 or 3 days after surgery	CS + chemical	0.6% DVT
Takahashi et al ³⁶	2012	Level IV	1975	Clinical and/or eCT/DD	1 week after surgery	None or CS	1.5% symptomatic PE in non-prophylaxis group and 0.2% symptomatic PE in CS group

continued

TABLE I (continued)

First author	Year	Level of Evidence	No cases	Methods of screening	Timing	Prophylaxis	Incidence of VTE
Houl et al ³⁷	2015	Level IV	5766	Clinical and/or DUS/eCT	NR	PCD	1.5% VTE (0.88% PE and 0.66% PE)
Hamidi et al ³⁸	2015	Level IV	89	DUS	NR	CA and Chemical or not	3.3% VTE
Weber et al ³⁹	2016	Level IV	107	Clinical and DUS, and or eCT	4 or 5 days after surgery	Mixed	3.7% VTE (1.9% DVT and 1.9% PE)
Liu et al ⁴⁰	2016	Level IV	396	DUS	Before surgery	NR	4% had DVT in patients with CSM preoperatively
Ikeda et al ¹⁸	2017	Level IV	194	DD combined with DUS	US 5 days; DD 1, 3, 7, 10, and 14 days after surgery	CS and PCD	29.4% DVT
Inoue et al ⁴¹	2018	Level IV	72	DD combined with eCT	CT: before and 3 days after surgery; DD: before and 1, 3, and 7 days after surgery	PCD	8.3% asymptomatic PE and 8.3% asymptomatic DVT
Koo et al ⁴²	2018	Level III	122	DD combined with DUS	7 days after surgery	NR	0.8% DVT in the TXA group and 1.2% DVT in the control group
Cheang et al ⁴³	2019	Level IV	170	DUS	3 and 7 days after surgery	Chemical	10% DVT
Zhang et al ⁴⁴	2021	Level IV	2053	Clinical + DUS	NR	None	2.39% DVT

*Level I is high-quality randomized control study; Level II, lesser quality randomized control trial, prospective comparative study, prospective study with historical controls; Level III, case control study, retrospective comparative study; Level IV, case series; Level V, expert opinion, case report. VTE=Venous thromboembolism; DUS=Duplex ultrasonography; CS=Compression stocking; DVT=Deep venous thrombosis; PCD=Pneumatic compression device; PE=Pulmonary embolism; eCT=enhance contrast computed tomography; US=Ultrasound; DD=D-dimer; NR=No record; CSM=Cervical spondylotic myelopathy; TXA=Tranexamic acid.

time, amount of bleeding, preoperative ambulatory status, usage of instrumentation, and preoperative serum levels of D-dimer were compared between the DVT and non-DVT groups to establish predictors for postoperative DVT. Cut-off value of the preoperative level of D-dimer was calculated using receiver operating curve (ROC) analysis. It was suggested that perioperative application of DUS for detecting DVT in the lower extremities should be performed in patients undergoing spine surgery who are female, non-ambulatory, and with higher preoperative D-dimer serum level. Inoue et al., examined changes in blood markers with PE or DVT after low-risk spine surgery, namely cervical laminoplasty or lumbar laminectomy⁴¹. Elevated D-dimer at postoperative days 3 and 7 was found to be a predictive factor for the early diagnosis of PE after spine

surgery. A retrospective study reported an incidence of asymptomatic DVT identified by duplex screening of 10% (45 of 458 trauma patients), significantly higher in older patients, those with major length of stay, higher injury scores and with spinal injury²³. The authors recommended surveillance in trauma patients with these risk factors.

There are other publications that recommend against routine screening for DVT in patients undergoing spine surgery. Kaabachi et al., investigated asymptomatic DVT and prothrombotic diseases in non-syndromic children undergoing scoliosis surgery³¹. The protocol was designed for active screening of DVT using color DUS on the day before surgery and repeated on the 3rd, 7th, and 15th day postoperatively. Evaluation of prothrombotic disorders included

antithrombin and protein-C activities, and total protein-S antigen level. No patient manifested clinical symptoms of VTE in their study. Preoperative Doppler and ultrasound examinations were normal in all patients. They concluded that VTE events are rare after scoliosis surgery, and routine screening is not justified. Ko et al., investigated the incidence of thromboembolism in patients who received tranexamic acid (TXA) after lumbar spine fusion and explored the diagnostic value of lower limb DUS as a screening test⁴². They found comparable incidence of VTE (0.8%) in the TXA and non-TXA groups, and they concluded that lower limb DUS was not recommended as a screening test of DVT because of high false-positive rate.

Based on the available literature, there does not seem to be a role for routine screening for DVT in patients undergoing spine surgery. Screening should be reserved for patients at high-risk of VTE, as determined by studies on the subject and highlighted above.

Andrea Angelini, Gentaro Kumagai, Olivier Q. Groot

References

1. Glotzbecker MP, Bono CM, Wood KB, Harris MB. Thromboembolic disease in spinal surgery: a systematic review. *Spine (Phila Pa 1976)*. 2009 Feb 1;34(3):291-303.
2. Nicol M, Sun Y, Craig N, Wardlaw D. Incidence of thromboembolic complications in lumbar spinal surgery in 1,111 patients. *Eur Spine J*. 2009 Oct;18(10):1548-52.
3. Leon L, Rodríguez H, Tawk RG, Ondra SL, Labropoulos N, Morasch MD. The prophylactic use of inferior vena cava filters in patients undergoing high-risk spinal surgery. *Ann Vasc Surg*. 2005 May;19(3):442-7.
4. Smith JS, Fu KM, Polly DW Jr, Sansur CA, Berven SH, Broadstone PA, Choma TJ, Goytan MJ, Noordeen HH, Knapp DR Jr, Hart RA, Donaldson WF 3rd, Perra JH, Boachie-Adjei O, Shaffrey Cl. Complication rates of three common spine procedures and rates of thromboembolism following spine surgery based on 108,419 procedures: a report from the Scoliosis Research Society Morbidity and Mortality Committee. *Spine (Phila Pa 1976)*. 2010 Nov 15;35(24):2140-9.
5. Oda T, Fujii T, Kato Y, Fujita S, Kanemitsu N. Deep venous thrombosis after posterior spinal surgery. *Spine (Phila Pa 1976)*. 2000 Nov 15;25(22):2962-7.
6. Kelly J, Rudd A, Lewis RR, Hunt BJ. Screening for subclinical deep-vein thrombosis. *QJM*. 2001 Oct;94(10):511-9.
7. Wada M, Iizuka M, Iwade Y, Yamakami I, Yoshinaga K, Saeki N. Effectiveness of deep vein thrombosis screening on admission to a rehabilitation hospital: a prospective study in 1043 consecutive patients. *Thromb Res*. 2013 Jun;131(6):487-92.
8. Matsumoto S, Suda K, Iimoto S, Yasui K, Komatsu M, Ushiku C, Takahata M, Kobayashi Y, Tojo Y, Fujita K, Minami A. Prospective study of deep vein thrombosis in patients with spinal cord injury not receiving anticoagulant therapy. *Spinal Cord*. 2015 Apr;53(4):306-9.
9. Becker DM, Philbrick JT, Bachhuber TL, Humphries JE. D-dimer testing and acute venous thromboembolism. A shortcut to accurate diagnosis? *Arch Intern Med*. 1996 May 13;156(9):939-46.
10. Furlan JC, Fehlings MG. Role of screening tests for deep venous thrombosis in asymptomatic adults with acute spinal cord injury: an evidence-based analysis. *Spine (Phila Pa 1976)*. 2007 Aug 1;32(17):1908-16.
11. Chen CJ, Wang CJ, Huang CC. The value of D-dimer in the detection of early deep-vein thrombosis after total knee arthroplasty in Asian patients: a cohort study. *Thromb J*. 2008 May 28;6:5.
12. Shiota N, Sato T, Nishida K, Matsuo M, Takahara Y, Mitani S, Murakami T, Inoue H. Changes in LPIA D-dimer levels after total hip or knee arthroplasty relevant to deep-vein thrombosis diagnosed by bilateral ascending venography. *J Orthop Sci*. 2002;7(4):444-50.
13. Goodacre S, Sampson F, Thomas S, van Beek E, Sutton A. Systematic review and meta-analysis of the diagnostic accuracy of ultrasonography for deep vein thrombosis. *BMC Med Imaging*. 2005 Oct 3;5:6.
14. Fraser DG, Moody AR, Morgan PS, Martel AL, Davidson I. Diagnosis of lower-limb deep venous thrombosis: a prospective blinded study of magnetic resonance direct thrombus imaging. *Ann Intern Med*. 2002 Jan 15;136(2):89-98.
15. Kumagai G, Wada K, Kudo H, Asari T, Ichikawa N, Ishibashi Y. D-dimer monitoring combined with ultrasonography improves screening for asymptomatic venous thromboembolism in acute spinal cord injury. *J Spinal Cord Med*. 2020 May;43(3):353-7.
16. Wei J, Li W, Pei Y, Shen Y, Li J. Clinical analysis of preoperative risk factors for the incidence of deep venous thromboembolism in patients undergoing posterior lumbar interbody fusion. *J Orthop Surg Res*. 2016 Jun 13;11(1):68.
17. Akins PT, Harris J, Alvarez JL, Chen Y, Paxton EW, Bernbeck J, Guppy KH. Risk Factors Associated With 30-day Readmissions After Instrumented Spine Surgery in 14,939 Patients: 30-day readmissions after instrumented spine surgery. *Spine (Phila Pa 1976)*. 2015 Jul 1;40(13):1022-32.
18. Ikeda T, Miyamoto H, Hashimoto K, Akagi M. Predictable factors of deep venous thrombosis in patients undergoing spine surgery. *J Orthop Sci*. 2017 Mar;22(2):197-200.
19. Zhang L, Cao H, Chen Y, Jiao G. Risk factors for venous thromboembolism following spinal surgery: A meta-analysis. *Medicine (Baltimore)*. 2020 Jul 17;99(29):e20954.
20. Yoshioka K, Murakami H, Demura S, Kato S, Tsuchiya H. Prevalence and risk factors for development of venous thromboembolism after degenerative spinal surgery. *Spine (Phila Pa 1976)*. 2015 Mar 1;40(5):E301-6.
21. Tominaga H, Setoguchi T, Tanabe F, Kawamura I, Tsuneyoshi Y, Kawabata N, Nagano S, Aematsu M, Yamamoto T, Yone K, Komiya S. Risk factors for venous thromboembolism after spine surgery. *Medicine (Baltimore)*. 2015 Feb;94(5):e466.
22. Ferree BA, Stern PJ, Jolson RS, Roberts JM 5th, Kahn A 3rd. Deep venous thrombosis after spinal surgery. *Spine (Phila Pa 1976)*. 1993 Mar 1;18(3):315-9.
23. Napolitano LM, Garlapati VS, Heard SO, Silva WE, Cutler BS, O'Neill AM, Anderson FA Jr, Wheeler HB. Asymptomatic deep venous thrombosis in the trauma patient: is an aggressive screening protocol justified? *J Trauma*. 1995 Oct;39(4):651-7, discussion :657-9.
24. Wood KB, Kos PB, Abnet JK, Ista C. Prevention of deep-vein thrombosis after major spinal surgery: a comparison study of external devices. *J Spinal Disord*. 1997 Jun;10(3):209-14.
25. Dearborn JT, Hu SS, Tribus CB, Bradford DS. Thromboembolic complications after major thoracolumbar spine surgery. *Spine (Phila Pa 1976)*. 1999 Jul 15;24(14):1471-6.
26. Lee HM, Suk KS, Moon SH, Kim DJ, Wang JM, Kim NH. Deep vein thrombosis after major spinal surgery: incidence in an East Asian population. *Spine (Phila Pa 1976)*. 2000 Jul 15;25(14):1827-30.
27. Epstein NE. Efficacy of pneumatic compression stocking prophylaxis in the prevention of deep venous thrombosis and pulmonary embolism following 139 lumbar laminectomies with instrumented fusions. *J Spinal Disord Tech*. 2006 Feb;19(1):28-31.
28. Platzer P, Thalhammer G, Jandl M, Obradovic A, Benesch T, Vecsei V, Gaebler C. Thromboembolic complications after spinal surgery in trauma patients. *Acta Orthop*. 2006 Oct;77(5):755-60.
29. Schizas C, Neumayer F, Kosmopoulos V. Incidence and management of pulmonary embolism following spinal surgery occurring while under chemical thromboprophylaxis. *Eur Spine J*. 2008 Jul;17(7):970-4.
30. Stowell CP, Jones SC, Enny C, Langhoff W, Leitz G. An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. *Spine (Phila Pa 1976)*. 2009 Nov 1;34(23):2479-85.
31. Kaabachi O, Alkaissi A, Koubaa W, Aloui N, Toumi NelH. Screening for deep venous thrombosis after idiopathic scoliosis surgery in children: a pilot study. *Paediatr Anaesth*. 2010 Feb;20(2):144-9.
32. Epstein NE, Staszewski H, Garrison M, Hon M. Pulmonary embolism diagnosed on computed tomography contrast angiography despite negative venous Doppler ultrasound after spinal surgery. *J Spinal Disord Tech*. 2011 Aug;24(6):358-62.
33. Yoshiiwa T, Miyazaki M, Takita C, Itonaga I, Tsumura H. Analysis of measured D-dimer levels for detection of deep venous thrombosis and pulmonary embolism after spinal surgery. *J Spinal Disord Tech*. 2011 Jun;24(4):E35-9.
34. Kim HJ, Walcott-Sapp S, Adler RS, Pavlov H, Boachie-Adjei O, Westrich GH. Thromboembolic Complications Following Spine Surgery Assessed with Spiral CT Scans: DVT/PE Following Spine Surgery. *HSS J*. 2011 Feb;7(1):37-40.
35. Al-Dujaili TM, Majer CN, Madhoun TE, Kassis SZ, Saleh AA. Deep venous thrombosis in spine surgery patients: incidence and hematoma formation. *Int Surg*. 2012 Apr-Jun;97(2):150-4.
36. Takahashi H, Yokoyama Y, Iida Y, Terashima F, Hasegawa K, Saito T, Suguro T, Wada A. Incidence of venous thromboembolism after spine surgery. *J Orthop Sci*. 2012 Mar;17(2):114-7.
37. Hohl JB, Lee JY, Rayappa SP, Nabb CE, Devin CJ, Kang JD, Ward WT, Donaldson WF 3rd. Prevalence of venous thromboembolic events after elective major thoracolumbar degenerative spine surgery. *J Spinal Disord Tech*. 2015 Jun;28(5):E310-5.

38. Hamidi S, Riazi M. Incidence of venous thromboembolic complications in instrumental spinal surgeries with preoperative chemoprophylaxis. *J Korean Neurosurg Soc.* 2015 Feb;57(2):114-8.
39. Weber B, Seal A, McGirr J, Fielding K. Case series of elective instrumented posterior lumbar spinal fusions demonstrating a low incidence of venous thromboembolism. *ANZ J Surg.* 2016 Oct;86(10):796-800.
40. Liu L, Liu YB, Sun JM, Hou HF, Liang C, Li T, Qi HT. Preoperative deep vein thrombosis in patients with cervical spondylotic myelopathy scheduled for spinal surgery. *Medicine (Baltimore).* 2016 Nov;95(44):e5269.
41. Inoue H, Watanabe H, Okami H, Kimura A, Seichi A, Takeshita K. D-dimer predicts pulmonary embolism after low-risk spine surgery. *Spine Surg Relat Res.* 2018 Feb 28;2(2):113-20.
42. Ko BS, Cho KJ, Kim YT, Park JW, Kim NC. Does Tranexamic Acid Increase the Incidence of Thromboembolism After Spinal Fusion Surgery? *Clin Spine Surg.* 2020 Mar;33(2):E71-5.
43. Cheang MY, Yeo TT, Chou N, Lwin S, Ng ZX. Is anticoagulation for venous thromboembolism safe for Asian elective neurosurgical patients? A single centre study. *ANZ J Surg.* 2019 Jul;89(7-8):919-24.
44. Zhang H, Weng H, Yu K, Qiu G. Clinical Risk Factors and Perioperative Hematological Characteristics of Early Postoperative Symptomatic Deep Vein Thrombosis in Posterior Lumbar Spinal Surgery. *Spine (Phila Pa 1976).* 2021 Oct 1; 46(19):E1042-8.

2 - Concerning VTE risk, which surgeries can be considered high-risk, and which surgeries can be considered low-risk in spine surgery?

Response/Recommendation: Concerning venous thromboembolism (VTE) risk in spine surgery, high-risk procedures include those performed for oncologic, traumatic, or infection, as well as those requiring intensive care unit (ICU) admission, multiple stages, or combined approaches. Lumbar procedures including long-segment fusions or procedures utilizing an anterior approach, as well as posterior cervical fusions, should also be considered high-risk. On the other hand, most elective pediatric procedures, microdiscectomies, anterior cervical fusions, and lumbar or cervical decompressions may be considered low-risk procedures.

Strength of Recommendation: Moderate.

Delegates vote: Agree 100.00% Disagree 0.00% Abstain 0.00% (Unanimous Strong Consensus).

Rationale: Patient characteristics (age, obesity, personal history of VTE, etc.), clinical factors (length of hospital stay, operative time, etc.), and neurologic impairment are associated with increased risk of postoperative VTE⁴⁵⁻⁴⁷. Nonetheless, there is no consensus regarding the VTE risk profile when it comes to surgical indications, operative techniques, and extent of surgery.

High-risk spine surgeries: Oncologic indication for spinal surgery has been shown to increase the risk of VTE with a reported incidence nearing 11.3%⁴⁸⁻⁵³. In a National Surgical Quality Improvement Project (NSQIP) database study of 22,434 patients, a diagnosis of tumor resulted in an odds ratio (OR) of 5.07 for postoperative VTE development, whereas a diagnosis of disseminated cancer carried an OR of 6.83⁴⁹. This relationship has also been elucidated separately for cervical and thoracolumbar procedures, with studies reporting OR of 5.2 or 1.8, respectively^{50,51}. Furthermore, any surgery for infection or requiring an ICU admission should be considered high-risk^{51,54,55}. Infection has been shown to increase VTE risk in multiple studies, with an OR of 18.5 in a 1:2 matched cohort of 85 VTE, and an incidence of 10.7% in a database study of 357,926 patients^{51,55}. Similarly, a retrospective study of 6,869 patients with 1,269 postoperative ICU

admissions reported a VTE incidence of 10.2% in the ICU group and 2.5% in the non-ICU group despite an increased use of chemoprophylaxis in the former group⁵⁴.

Trauma or fracture as an indication for spinal surgery has also been shown to increase the risk of VTE, and these procedures should therefore be considered high-risk^{51,53,56-58}. In a retrospective study of 7,156 patients, a diagnosis of fracture was associated with an increased risk of VTE (OR 8.3) despite an increased use of chemoprophylaxis in this group of patients⁵⁸. In another retrospective study of 195 patients, the rate of VTE was 9.2% among fracture patients compared to 2.3% in the non-fracture group (OR 4.5)⁵⁷. Fracture has also been shown to be an independent predictor of pulmonary embolism (PE) (OR 6.9) in a retrospective study of 6,869 patients⁵³.

Staged procedures and combined surgical approaches have also been shown to increase the risk of VTE^{45,51,55,59,60}. A 1:2 matched cohort analysis of 85 postoperative VTE found both staged surgery (OR 28.0) and combined approach (OR 7.5) to increase the risk of VTE⁵¹. Additionally, multiple studies have shown that lumbar procedures have an increased risk of VTE compared to cervical procedures^{46,48,55,58,61-65}. However, an anterior approach to the lumbar spine and a posterior approach to the cervical spine have been shown to increase VTE risk compared to their posterior and anterior counterparts, respectively^{45,55,66}. A Nationwide Inpatient Sample (NIS) database study of 273,396 cervical procedures found a postoperative VTE incidence of 2.0% in posterior cervical fusion compared to 0.4% in anterior cervical discectomy and fusion (ACDF)⁶⁶.

The number of surgical levels is another factor that could increase the risk of VTE^{51,57,67-69}. A 1:2 matched cohort analysis of 85 postoperative VTE identified two or more surgical levels as a risk factor (OR 7.5), and other studies reported an increased risk using various cut-offs for number of levels^{51,55,67-69}. Furthermore, one French database demonstrated a “dose-effect” for pedicle screw implantation, with a 40% increased risk of VTE for 1 - 5 screws, 69% for 6 - 9 screws, and 117% for > 10 screws⁴⁵.

Low-risk spine surgeries: While most elective pediatric procedures are considered low VTE risk^{70,71}, patients undergoing surgery for congenital scoliosis, syndromic scoliosis/kyphoscoliosis, thoracolumbar fractures, and the ones requiring ICU admission or prolonged immobilization have a relatively increased VTE risk compared to those undergoing surgery for idiopathic scoliosis⁷². Additionally, microdiscectomy, ACDF, and lumbar or cervical decompression (i.e., laminectomy, hemilaminectomy and laminotomy) have demonstrated a low risk of postoperative VTE, with rates < 0.2% for each procedure⁷³. Some studies have suggested that fusion procedures may increase the risk of VTE^{55,67,74,75}. However, this claim has been widely disputed, and one retrospective study of 6,869 patients found that fusion actually decreased the risk of 30-day readmission for VTE (OR 0.59). Furthermore, no increased risk has been shown in revision procedures⁵⁵. Consequently, the VTE risk profile of spinal fusion and revision surgery could not be absolutely determined, and surgeons should rather consider the surgical indication, location,

approach, and number of levels when performing VTE risk assessment.

The explanation for these relationships is multifactorial. When evaluating these surgeries, it is important to consider the Virchow's Triad, which constitutes blood flow stasis, endothelial injury, and hypercoagulability⁷⁶. Postoperative immobility may explain the increased risk in traumatic, ICU, multistage, combined approach, and long-segment procedures, while hypercoagulability may explain the increased risk in oncologic, traumatic, and infectious procedures^{77,78}. Further research including various surgical procedures and VTE risk assessments should be conducted to further delineate high- and low-risk procedures within spine surgery.

Jose A. Canseco, Gregory R. Toci, Olivier Q. Groot, Joseph H. Schwab

References

45. Bouyer B, Rudnichi A, Dray-Spira R, Zureik M, Coste J. Thromboembolic risk after lumbar spine surgery: a cohort study on 325 000 French patients. *J Thromb Haemost*. 2018 Jun 12;16(8):1537-45.
46. Buchanan IA, Lin M, Donoho DA, Ding L, Giannotta SL, Attenello F, Mack WJ, Liu JC. Venous Thromboembolism After Degenerative Spine Surgery: A Nationwide Readmissions Database Analysis. *World Neurosurg*. 2019 May;125:e165-74.
47. Glotzbecker MP, Bono CM, Wood KB, Harris MB. Thromboembolic disease in spinal surgery: a systematic review. *Spine (Phila Pa 1976)*. 2009 Feb 1;34(3):291-303.
48. Yoshioka K, Murakami H, Demura S, Kato S, Hayashi H, Inoue K, Ota T, Shinmura K, Yokogawa N, Fang X, Tsuchiya H. Comparative study of the prevalence of venous thromboembolism after elective spinal surgery. *Orthopedics*. 2013 Feb; 36(2):e223-8.
49. Piper K, Algattas H, DeAndrea-Lazarus IA, Kimmell KT, Li YM, Walter KA, Silberstein HJ, Vates GE. Risk factors associated with venous thromboembolism in patients undergoing spine surgery. *J Neurosurg Spine*. 2017 Jan;26(1):90-6.
50. Sebastian AS, Currier BL, Kakar S, Nguyen EC, Wagie AE, Habermann ES, Nassr A. Risk Factors for Venous Thromboembolism following Thoracolumbar Surgery: Analysis of 43,777 Patients from the American College of Surgeons National Surgical Quality Improvement Program 2005 to 2012. *Global Spine J*. 2016 Dec; 6(8):738-43.
51. Sebastian AS, Currier BL, Clarke MJ, Larson D, Huddleston PM 3rd, Nassr A. Thromboembolic Disease after Cervical Spine Surgery: A Review of 5,405 Surgical Procedures and Matched Cohort Analysis. *Global Spine J*. 2016 Aug;6(5):465-71.
52. Groot OQ, Ogink PT, Paulino Pereira NR, Ferrone ML, Harris MB, Lozano-Calderon SA, Schoenfeld AJ, Schwab JH. High Risk of Symptomatic Venous Thromboembolism After Surgery for Spine Metastatic Bone Lesions: A Retrospective Study. *Clin Orthop Relat Res*. 2019 Jul;477(7):1674-86.
53. Cloney MB, Driscoll CB, Yamaguchi JT, Hopkins B, Dahdaleh NS. Comparison of inpatient versus post-discharge venous thromboembolic events after spinal surgery: A single institution series of 6869 consecutive patients. *Clin Neurol Neurosurg*. 2020 Sep;196:105982.
54. Cloney MB, Goergen J, Hopkins BS, Dhillon ES, Dahdaleh NS. Factors associated with venous thromboembolic events following ICU admission in patients undergoing spinal surgery: an analysis of 1269 consecutive patients. *J Neurosurg Spine*. 2018 Oct 12;30(1):99-105.
55. Schairer WW, Pedtke AC, Hu SS. Venous Thromboembolism After Spine Surgery. *Spine (Phila Pa 1976)*. 2014 May 15;39(11):911-8.
56. Cloney M, Dhillon ES, Roberts H, Smith ZA, Koski TR, Dahdaleh NS. Predictors of Readmissions and Reoperations Related to Venous Thromboembolic Events After Spine Surgery: A Single-Institution Experience with 6869 Patients. *World Neurosurg*. 2018 Mar;111:e91-7.
57. Cloney MB, Yamaguchi JT, Dhillon ES, Hopkins B, Smith ZA, Koski TR, Dahdaleh NS. Venous thromboembolism events following spinal fractures: A single center experience. *Clin Neurol Neurosurg*. 2018 Nov;174:7-12.
58. Fischer CR, Wang E, Steinmetz L, Vasquez-Montes D, Buckland A, Bendo J, Frempong-Boadu A, Errico T, FISCHER CR. Prevalence of Risk Factors for Hospital-Acquired Venous Thromboembolism in Neurosurgery and Orthopedic Spine Surgery Patients. *Int J Spine Surg*. 2020 Feb 29;14(1):79-86.
59. Edwards CC 2nd, Lessing NL, Ford L, Edwards CC. Deep Vein Thrombosis After Complex Posterior Spine Surgery: Does Staged Surgery Make a Difference? *Spine Deform*. 2018 Mar - Apr;6(2):141-7.
60. Gephart MGH, Zygorakis CC, Arrigo RT, Kalanithi PSA, Lad SP, Boakye M. Venous thromboembolism after thoracic/thoracolumbar spinal fusion. *World Neurosurg*. 2012 Nov;78(5):545-52.
61. Platzer P, Thalhammer G, Jandl M, Obradovic A, Benesch T, Vecsei V, Gaebler C. Thromboembolic complications after spinal surgery in trauma patients. *Acta Orthop*. 2006 Oct;77(5):755-60.
62. Yoshioka K, Murakami H, Demura S, Kato S, Tsuchiya H. Prevalence and risk factors for development of venous thromboembolism after degenerative spinal surgery. *Spine (Phila Pa 1976)*. 2015 Mar 1;40(5):E301-6.
63. Wang T, Yang SD, Huang WZ, Liu FY, Wang H, Ding WY. Factors predicting venous thromboembolism after spine surgery. *Medicine (Baltimore)*. 2016 Dec; 95(52):e5776.
64. Xin WQ, Xin QQ, Ming HL, Gao YL, Zhao Y, Gao YK, Yang X. Predictable Risk Factors of Spontaneous Venous Thromboembolism in Patients Undergoing Spine Surgery. *World Neurosurg*. 2019 Jul;127:451-63.
65. Oda T, Fujii T, Kato Y, Fujita S, Kanemitsu N. Deep venous thrombosis after posterior spinal surgery. *Spine (Phila Pa 1976)*. 2000 Nov 15;25(22):2962-7.
66. Oglesby M, Fineberg SJ, Patel AA, Pelton MA, Singh K. The incidence and mortality of thromboembolic events in cervical spine surgery. *Spine (Phila Pa 1976)*. 2013 Apr 20;38(9):E521-7.
67. Rojas-Tomba F, Gormaz-Talavera I, Menéndez-Quintanilla IE, Moriel-Durán J, García de Quevedo-Puerta D, Villanueva-Pareja F. [Incidence and risk factors of venous thromboembolism in major spinal surgery with no chemical or mechanical prophylaxis.] *Rev Esp Cir Ortop Traumatol*. 2016 Mar-Apr;60(2):133-40. [Spanish.]
68. Hohl JB, Lee JY, Rayappa SP, Nabb CE, Devin CJ, Kang JD, Ward WT, Donaldson WF 3rd. Prevalence of venous thromboembolic events after elective major thoracolumbar degenerative spine surgery. *J Spinal Disord Tech*. 2015 Jun;28(5):E310-5.
69. Yamasaki K, Hoshino M, Omori K, Igarashi H, Tsuruta T, Miyakata H, Nemoto Y, Matsuzaki H, Iriuchishima T. Prevalence and risk factors of deep vein thrombosis in patients undergoing lumbar spine surgery. *J Orthop Sci*. 2017 Nov;22(6):1021-5.
70. Shore BJ, Hall M, Matheny TH, Snyder B, Trenor CC 3rd, Berry JG. Incidence of Pediatric Venous Thromboembolism After Elective Spine and Lower-Extremity Surgery in Children With Neuromuscular Complex Chronic Conditions: Do we Need Prophylaxis? *J Pediatr Orthop*. 2020 May/Jun;40(5):e375-9.
71. Erkilinc M, Clarke A, Poe-Kochert C, Thompson GH, Hardesty CK, O'Malley N, Mistovich RJ. Is There Value in Venous Thromboembolism Chemoprophylaxis After Pediatric Scoliosis Surgery? A 28-Year Single Center Study. *J Pediatr Orthop*. 2021 Mar 1;41(3):138-42.
72. Jain A, Karas DJ, Skolasky RL, Sponseller PD. Thromboembolic complications in children after spinal fusion surgery. *Spine (Phila Pa 1976)*. 2014 Jul 15;39(16):1325-9.
73. Smith JS, Fu KMG, Polly DW Jr, Sansur CA, Berven SH, Broadstone PA, Choma TJ, Goytan MJ, Noordeen HH, Knapp DR Jr, Hart RA, Donaldson WF 3rd, Perra JH, Boachie-Adjei O, Shaffrey CI. Complication rates of three common spine procedures and rates of thromboembolism following spine surgery based on 108,419 procedures: a report from the Scoliosis Research Society Morbidity and Mortality Committee. *Spine (Phila Pa 1976)*. 2010 Nov 15;35(24):2140-9.
74. Zhang L, Cao H, Chen Y, Jiao G. Risk factors for venous thromboembolism following spinal surgery: A meta-analysis. *Medicine (Baltimore)*. 2020 Jul 17;99(29):e20954.
75. Sansone JM, del Rio AM, Anderson PA. The prevalence of and specific risk factors for venous thromboembolic disease following elective spine surgery. *J Bone Joint Surg Am*. 2010 Feb;92(2):304-13.
76. Bagot CN, Arya R. Virchow and his triad: a question of attribution. *Br J Haematol*. 2008 Oct;143(2):180-90.
77. Kawai K, Watanabe T. Colorectal cancer and hypercoagulability. *Surg Today*. 2014 May;44(5):797-803.
78. Chu AJ. Tissue factor, blood coagulation, and beyond: an overview. *Int J Inflamm*. 2011;2011:367284.

3 - Does the concern for epidural hematoma influence the choice for VTE prophylaxis after spine surgery?

Response/Recommendation: Epidural hematoma is a feared yet rare postoperative complication after spinal surgery, with symptomatic rates ranging from 0% to 1.8%. Although there is no published evidence to precisely define the safety of chemoprophylaxis, it seems that postoperative anticoagulants in non-therapeutic doses can be administered without an increased risk of spinal epidural hematoma. Prospective studies are required to

better balance the risks and benefits of prophylactic anticoagulants regarding spinal epidural hematomas and Venous thromboembolism (VTE).

Strength of Recommendation: Limited.

Delegates vote: Agree 96.30% Disagree 0.00% Abstain 3.70% (Strong Consensus).

Rationale: The key words used in our search of PubMed, Cochrane Library, and Embase were “*epidural hematoma*”, “*spine surgery*”, and “*venous thromboembolism*”. Studies were included if they investigated spinal epidural hematomas and chemoprophylaxis of any sort. Studies were not excluded if they did not clearly report VTE or the method of VTE screening. Case reports and series were excluded. References of included studies were checked. Various data was extracted from the included studies including method of chemoprophylaxis, VTE screening, and rates of postoperative symptomatic VTE and epidural hematoma. In total, 14 studies were included for data extraction after full review (Table II).

Spine surgeons must weigh the risks of chemoprophylaxis, which include bleeding and hemorrhagic complications such as spinal epidural hematoma, against the benefits of preventing VTE. Studies report a symptomatic postoperative VTE rate of 1.5% - 31% and symptomatic spinal epidural hematoma of 0% - 1.8%⁷⁹⁻⁸³. Both rates are noteworthy, especially considering that epidural hematoma can lead to severe neurologic complications. As a result, precise indication, agent, dose, and timing for prophylaxis following spinal surgery is essential^{181,84}.

In 1998, Agnelli et al.⁸⁵, compared in a level I, multicenter randomized controlled trial the use of compression stockings (CS) alone (n = 15) to enoxaparin 40 mg daily started within 24 hours for 7 days and CS (n = 31) following elective spinal cord procedures. No patients developed a spinal epidural hematoma and VTE rate was unknown. Not specific to spinal procedures, the authors concluded that enoxaparin combined with CS was more effective in preventing symptomatic VTE than CS alone and did not increase the risk for excessive bleeding following intracranial and spinal procedures.

In a recent 2021 study by Thota et al.⁸⁶, 888 patients who received anticoagulation were propensity score matched to 888 patients receiving no anticoagulation in elective spine surgeries. No difference was found in symptomatic VTE rate; however, unplanned reoperation for hematoma were greater for those who received pharmacological anticoagulation (odds ratio [OR] = 7.5, 95% confidence interval [CI] = 2.0 - 28.3, p < 0.01).

Cox et al.⁸⁷, compared VTE and epidural hematoma rate before (provider dependent, 24 hours after surgery) and after a protocol change (5,000 U heparin administered subcutaneously 3 times daily, with the first dose given immediately postoperatively). VTE rate decreased in the more aggressive protocol (3.3% vs. 1.5%; p < 0.01) and no difference was found in epidural hematoma occurrence (0.6% vs. 0.4%; p = 0.58). Gerlach et al.⁸⁸, retrospectively included 1,954 spinal procedures on different levels. All patients received routinely 0.3 mL nadroparin within 24 hours of surgery and compression stocking. Only 1 (0.05%) patient had a DVT, and 8 (0.4%)

patients developed epidural hematoma, of which 3 patients were discharged with residual neurological impairment. The authors state that early nadroparin is safe and is not associated with an increased risk of postoperative epidural hematoma.

Uribe et al.⁸⁹, examined delayed postoperative spinal epidural hematoma, defined as 3 days after surgery, in 4,018 patients that awoke from surgery neurologically unchanged. No standard prophylaxis protocol was used and VTE events were not investigated. Seven (0.2%) patients developed a spinal epidural hematoma of which 4 had received subcutaneous heparin. Dhillon et al., compared 1,904 (28%) patients who received various anticoagulants with 4,965 (72%) patients who received none. The risk of epidural hematomas in both groups was low (both 0.2%; p = 0.62). The authors state that administering 5,000 U of heparin, 40 mg of enoxaparin, 2,500 or 5,000 U of dalteparin, or 2.5 mg of fondaparinux within 3 days of surgery was safe for patients undergoing spinal procedures.

Most studies suggested no difference in epidural hematoma rates between postoperative chemoprophylaxis and no prophylaxis^{82,83,85,87-96}, except for Hohenberger et al.⁹⁷. This retrospective study investigated epidural hematomas in a matched 1:3 case control study of 6,024 patients undergoing spinal decompression surgery. Forty-two patients with an epidural hematoma were matched with 126 patients with the same surgical procedure, year, sex, and age. Anticoagulation use (acetylsalicylic acid, coumadin, and rivaroxaban) were associated with an increased risk of epidural hematomas (OR, 3.32 [1.50 - 7.38]; p < 0.01). However, the VTE rate was not provided, and controlling for confounding factors was not performed. In three similar case control studies, use of anticoagulants was not associated with an increased risk for epidural hematomas. (Awad, Kao, and Wang)⁹⁸⁻¹⁰⁰. For instance, a similar 1:3 case control study demonstrated that 32 patients with and 102 matched controls without spinal epidural hematoma received respectively 41% (13/32), and 51% (52/102) anticoagulation⁹⁸.

Of interest to note is the study from Cunningham et al.¹⁰¹, that investigated not the influence of postoperative but preoperative chemoprophylaxis on VTE and epidural hematoma rate. In 3,870 elective spinal procedures, 37% (1,428) received preoperative chemoprophylaxis. Nineteen (0.5%) patients had a VTE of whom 9 (47%) had preoperative chemoprophylaxis (p = 0.35). Sixteen (0.4%) patients developed a spinal epidural hematoma, of whom 7 (44%) received preoperative heparin 5,000 units subcutaneously (p = 0.61). The authors conclude that preoperative chemoprophylaxis does not influence the rate of VTE and spinal epidural hematomas.

Several studies identified risk factors for development of spinal epidural hematomas, including perioperative transfusion⁹¹, high intraoperative blood loss (> 1 liter)⁹⁸, pathologic coagulation values, cigarette smoking⁹⁷, intraoperative use of gelfoam for dura coverage, postoperative drain output¹⁰⁰, increased age, obesity, multilevel surgery, and dural tear repair¹⁰². Although no studies have specifically investigated anticoagulation use in these high-risk patients, one may want to refrain from administering chemoprophylaxis.

TABLE II Characteristics of included studies (n = 14)

Author, year	Level of evidence	Patients	Type of surgery	Chemoprophylaxis	Methods of screening	VTE %(n)	Epidural hematoma %(n)
Agnelli, 1998 ⁸⁵	I	15	NS	TED	Routinely imaging on day 8	NA	0%
		31		TED + LMWH within 24 hours		NA	0%
Al-Dujaili, 2012 ⁸²	IV	158	NS	CS + LMWH 40 mg within 12h	Clinically + routine US	DVT = 0.6% (1)	1.8% (3)
Amiri, 2013 ⁹⁰	IV	4,568	Various	Anticoagulant therapy within 24 h	NS	NA	0.2% (10)
Cloney, 2018 ⁹¹	IV	6,869	Various	Various 28% (1,904); none 72% (4,965)*	NS	2.5% (170)	0.2% (13)
Cox, 2014 ⁸⁷	IV	941	NS	CS + 5,000U heparin 3x daily after 24h	NS	3.3% (31); DVT = 2.7% (25); PE = 0.6% (6)	0.6% (6)
		992		Provider dependent 24 h after OR		1.5% (15)	0.4% (4)
Dhillon, 2017 ⁹²	IV	1,904	Various	Chemoprophylaxis#	NS	3.6% (69); DVT = 3.2% (60); PE = 0.8% (15)	0.2% (4)
		4,965		None		2.0% (101); DVT = 1.7% (82); PE = 0.6% (30)	0.2% (9)
Dickman, 1992 ⁹³	IV	104	Posterior pedicle screw fixation	PCS	NS	DVT = 2.9% (3)	1.0% (1)
Gerlach, 2004 ⁸⁸	IV	1,954	Various, multilevel	LMWH within 24 hours + CS	Clinically	DVT = 0.1% (1)	0.7% (13)
Groot, 2019 ⁸⁵	IV	637	Spinal metastases	Various 86% (548); none 14% (89)	Clinically	11% (72); DVT = 6.1% (40); PE = 6.0% (38)	1.1% (7)
Park, 2019 ⁹⁴	IV	2,1261	Various	Various 7.9% (1,678); none 92.1% (19,583)*	NS	2.1% (444); DVT = 1.7% (370); PE = 0.4% (84)	0
Platzer, 2006 ⁹⁵	IV	978	Trauma	LMWH (792); LMWH + CS (153)	Clinically	2.2% (22); DVT = 1.7% (17); PE = 0.9% (9)	0
Uribe, 2003 ⁸⁹	IV	4,018	NS	NS; 4 SEH cases with SCH	NS	NA	0.2% (7)
Strom, 2013 ⁹⁶	IV	367	Cervical and lumbar decompression	LMWH within 36 h	NS	3.8% (14); DVT = 2.7% (10); PE = 1.1% (4)	0
Thota, 2021 ⁸⁶	IV	888~	Elective	Any anticoagulation	Clinically	0.9% (8); PE = 0.3% (3)	2.0% (18)
		888		None		1.0% (9); PE = 0.3% (3)	0.2% (2)

*chemoprophylaxis was defined as 5,000 U heparin, 40 mg enoxaparin, 2,500 U or 5,000 U dalteparin, or 2.5 mg fondaparinux given from 1 day prior to 3 days post operation. #chemoprophylaxis was defined as the following agents given between 1 day before and 3 days after surgery: 5,000 U of heparin, 40 mg of enoxaparin, 2,500 or 5,000 U of dalteparin, or 2.5mg of fondaparinux. Chemoprophylaxis was defined as any of the following medications: aspirin, direct thrombin inhibitor, factor Xa inhibitors, low-molecular-weight heparin, unfractionated heparins, and warfarin. ~Propensity score matched starting with 3,536 patients that matched a single patient who did not receive anticoagulation to a single patient who did. All presented VTE rates are symptomatic. n=number; VTE=Venous thromboembolism; NS=Not specified; TED=Thigh length compression; LMWH=Low-molecular-weight heparin; NA=Not available; CS=Compression stockings; US=ultrasound screening; DVT=Deep venous thrombosis; PE=Pulmonary embolism; OR=Operative room; PCS=Pneumatic compression stockings; SHE=Spinal epidural hematoma; SCH=Subcutaneous heparin.

Conclusions from the included studies are difficult given the heterogeneity of methods of prophylaxis and VTE screening, surgical procedures, and patient population. In particular, the timing and dose of chemoprophylaxis vary between studies or are not specified. Furthermore, quality of the individual studies is poor, and the level of evidence is low. The fact that spinal epidural hematomas are relatively rare and potentially life threatening further complicates investigation of this outcome in a meaningful way⁸¹. For example, a clinical trial design comparing two different prophylaxis strategies would require 18,519 patients (difference 0.2% vs. 0.1%) or 1,002 patients (difference 3.6% vs. 1.8%) for 80% power.

In view of these limitations, future research should provide granular data on type, dosage and timing of anticoagulants and stratified epidural hematoma results by indication and chemoprophylaxis usage. Given the severe neurologic complications of epidural hematoma, prospective studies are also needed to delineate the safe use of various anticoagulants after surgery as well as their ideal timing and dosage.

Olivier Q. Groot, David W. Polly Jr., Joseph H. Schwab

References

79. Nicol M, Sun Y, Craig N, Wardlaw D. Incidence of thromboembolic complications in lumbar spinal surgery in 1,111 patients. *Eur Spine J*. 2009 Oct; 18(10):1548-52.
80. Leon L, Rodriguez H, Tawk RG, Ondra SL, Labropoulos N, Morasch MD. The prophylactic use of inferior vena cava filters in patients undergoing high-risk spinal surgery. *Ann Vasc Surg*. 2005 May;19(3):442-7.
81. Glotzbecker MP, Bono CM, Wood KB, Harris MB. Thromboembolic disease in spinal surgery: a systematic review. *Spine (Phila Pa 1976)*. 2009 Feb 1;34(3):291-303.
82. Al-Dujaili TM, Majer CN, Madhoun TE, Kassis SZ, Saleh AA. Deep venous thrombosis in spine surgery patients: incidence and hematoma formation. *Int Surg*. 2012 Apr-Jun;97(2):150-4.
83. Groot OQ, Ogink PT, Paulino Pereira NR, Ferrone ML, Harris MB, Lozano-Calderon SA, Schoenfeld AJ, Schwab JH. High Risk of Symptomatic Venous Thromboembolism After Surgery for Spine Metastatic Bone Lesions: A Retrospective Study. *Clin Orthop Relat Res*. 2019 Jul;477(7):1674-86.
84. Glotzbecker MP, Bono CM, Harris MB, Brick G, Heary RF, Wood KB. Surgeon practices regarding postoperative thromboembolic prophylaxis after high-risk spinal surgery. *Spine (Phila Pa 1976)*. 2008 Dec 15;33(26):2915-21.
85. Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A, Beltrametti C, Damiani M, Andrioli GC, Pugliese R, Iorio A, Brambilla G. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. *N Engl J Med*. 1998 Jul 9;339(2):80-5.
86. Thota DR, Bagley CA, Tamimi MA, Nakonezny PA, Van Hal M. Anticoagulation in Elective Spine Cases: Rates of Hematomas Versus Thromboembolic Disease. *Spine (Phila Pa 1976)*. 2021 Jul 1;46(13):901-6.
87. Cox JB, Weaver KJ, Neal DW, Jacob RP, Hoh DJ. Decreased incidence of venous thromboembolism after spine surgery with early multimodal prophylaxis: Clinical article. *J Neurosurg Spine*. 2014 Oct;21(4):677-84.
88. Gerlach R, Raabe A, Beck J, Woszczyk A, Seifert V. Postoperative nadroparin administration for prophylaxis of thromboembolic events is not associated with an increased risk of hemorrhage after spinal surgery. *Eur Spine J*. 2004 Feb;13(1):9-13.
89. Uribe J, Moza K, Jimenez O, Green B, Levi AD. Delayed postoperative spinal epidural hematomas. *Spine J*. 2003 Mar-Apr;3(2):125-9.
90. Amiri AR, Fouyas IP, Cro S, Casey ATH. Postoperative spinal epidural hematoma (SEH): incidence, risk factors, onset, and management. *Spine J*. 2013 Feb;13(2):134-40.
91. Cloney M, Dhillon ES, Roberts H, Smith ZA, Koski TR, Dahdaleh NS. Predictors of Readmissions and Reoperations Related to Venous Thromboembolic Events After Spine Surgery: A Single-Institution Experience with 6869 Patients. *World Neurosurg*. 2018 Mar;111:e91-7.
92. Dhillon ES, Khanna R, Cloney M, Roberts H, Cybulski GR, Koski TR, Smith ZA, Dahdaleh NS. Timing and risks of chemoprophylaxis after spinal surgery: a single-center experience with 6869 consecutive patients. *J Neurosurg Spine*. 2017 Dec; 27(6):681-93.

93. Dickman CA, Fessler RG, MacMillan M, Haid RW. Transpedicular screw-rod fixation of the lumbar spine: operative technique and outcome in 104 cases. *J Neurosurg*. 1992 Dec;77(6):860-70.
94. Park JH, Lee KE, Yu YM, Park YH, Choi SA. Incidence and Risk Factors for Venous Thromboembolism After Spine Surgery in Korean Patients. *World Neurosurg*. 2019 Aug;128:e289-307.
95. Platzer P, Thalhammer G, Jandl M, Obradovic A, Benesch T, Vecsei V, Gaebler C. Thromboembolic complications after spinal surgery in trauma patients. *Acta Orthop*. 2006 Oct;77(5):755-60.
96. Strom RG, Frempong-Boadu AK. Low-molecular-weight heparin prophylaxis 24 to 36 hours after degenerative spine surgery: risk of hemorrhage and venous thromboembolism. *Spine (Phila Pa 1976)*. 2013 Nov 1;38(23):E1498-502.
97. Hohenberger C, Zeman F, Höhne J, Ullrich OW, Brawanski A, Schebesch KM. Symptomatic Postoperative Spinal Epidural Hematoma after Spinal Decompression Surgery: Prevalence, Risk Factors, and Functional Outcome. *J Neurol Surg A Cent Eur Neurosurg*. 2020 Jul;81(4):290-6.
98. Awad JN, Kebaish KM, Donigan J, Cohen DB, Kostuik JP. Analysis of the risk factors for the development of post-operative spinal epidural haematoma. *J Bone Joint Surg Br*. 2005 Sep;87(9):1248-52.
99. Wang L, Wang H, Sun Z, Chen Z, Sun C, Li W. Incidence and Risk Factors for Symptomatic Spinal Epidural Hematoma Following Posterior Thoracic Spinal Surgery in a Single Institute. *Global Spine J*. 2020 Dec 17:2192568220979141.
100. Kao FC, Tsai TT, Chen LH, Lai PL, Fu TS, Niu CC, Ho NY, Chen WJ, Chang CJ. Symptomatic epidural hematoma after lumbar decompression surgery. *Eur Spine J*. 2015 Feb;24(2):348-57.
101. Cunningham JE, Swamy G, Thomas KC. Does preoperative DVT chemoprophylaxis in spinal surgery affect the incidence of thromboembolic complications and spinal epidural hematomas? *J Spinal Disord Tech*. 2011 Jun; 24(4):E31-4.
102. Knusel K, Du JY, Ren B, Kim CY, Ahn UM, Ahn NU. Symptomatic Epidural Hematoma after Elective Posterior Lumbar Decompression: Incidence, Timing, Risk Factors, and Associated Complications. *HSS J*. 2020 Dec;16(Suppl 2):230-7.

4 - When can VTE chemoprophylaxis, if to be used, be started following spine procedures?

Response/Recommendation: Venous Thromboembolism (VTE) chemoprophylaxis can probably be started within 24 - 48 hours following elective lumbar fusions, and within 48 hours following patients considered to be higher risk with bleeding. Chemoprophylaxis benefits should be carefully weighed against the risks of bleeding and hematoma formation.

Strength of Recommendation: Limited.

Delegates vote: Agree 88.46% Disagree 0.00% Abstain 11.54% (Strong Consensus).

Rationale: VTE is a significant adverse event after spine surgery that might be minimized with the use of appropriate prophylaxis regimen. However, the use of prophylaxis needs to be balanced by the risks associated with any intervention, such as bleeding, wound issues, etc. In spine surgery, there is particular concern about the possibility of hematoma which could cause compression of the spinal cord/nerves and the potential of neurologic sequelae.

The risk/benefit considerations of using VTE prophylaxis are dependent on understanding the incidence of this adverse outcome, as well as the associated risks; unfortunately, both of these factors are reported with variable numbers in the literature. Other subgroups are evaluating which specific agents for VTE chemoprophylaxis that should be considered following spine surgery, what screening is recommended, and if there are surgical/procedural/presentation variables that should influence the decision. This sub-group is asked to evaluate the literature regarding when VTE chemoprophylaxis can be started following spine procedures, if it is to be used.

Evaluation of the literature: If pursued, VTE chemoprophylaxis is most relevant during the time of greatest risk. An evaluation of the National Surgical Quality Improvement Program (NSQIP) database revealed that deep venous thrombosis (DVT) was diagnosed a median of 10.5 days after anterior cervical surgery and 8 days after posterior lumbar surgery¹⁰³. The first days were not high incidence, but there could be a delay from onset to detection, so it is difficult to know what to conclude from this information.

A recent survey study of 370 neurosurgeons highlighted the variation in thoughts on the posed question regarding safe timing of chemoprophylaxis following spine surgery¹⁰⁴. For uncomplicated elective spine surgery, most respondents are comfortable starting chemical prophylaxis on postoperative day 1 (59.1%), followed by day 2 (23.5%) and day 3 (9.4%), with a range of 0 – 14 days (mean 1.6 days). Those who were more senior in their careers recommended later start of chemoprophylaxis.

Another survey study of 193 orthopaedic and neurosurgical spine surgeons asked similar questions for timing of starting chemoprophylaxis after high-risk spinal surgery¹⁰⁵. The most common response was 48 hours after surgery (21 of 94, 22%). However, individual responses varied widely: 12% chose less than 24 hours, 15% chose 24 hours, 13% chose 72 hours, and 10% chose 96 hours. Some indicated they would start chemoprophylaxis before surgery, whereas others responded they would never use it. The most common basis for this decision was noted to be personal experience.

In terms of retrospective reviews, one group evaluated patients who underwent elective one- or two-stage lumbar spinal fusions at a high-volume single institution¹⁰⁶. This group found the odds of developing a VTE within 30 day was reduced in those who received chemoprophylaxis within 24 hours of surgery (odds ratio = 0.189, $p = 0.025$) with no difference in bleeding rates. In a trauma population, one study suggested starting chemoprophylaxis within 48 hours of surgery¹⁰⁷.

Another retrospective, single-institution study found higher prevalence of 30-day VTE in those who received chemoprophylaxis 1 day before to 3 days after surgery to be higher than the non-chemoprophylaxis group (presumably related to differential in populations who were not randomized) but no difference in the rates of epidural hematoma¹⁰⁸. Other studies have also found no increase in epidural hematoma with chemoprophylaxis^{108,109}, but at least one found the rate of epidural hematoma to be increased¹¹⁰. Unfortunately, these studies did not specifically assess the variable of when the chemoprophylaxis was started.

Conclusions: There are probably different risk/benefit considerations for chemoprophylaxis based on the risk inherent to patient sub-populations of patients undergoing spine surgery. This becomes a balance of minimizing VTE and avoiding epidural hematoma. No prospective study is identified to help answer this question. Retrospective studies seem to suggest that VTE chemoprophylaxis can be started within 24 or 48 hours. Survey studies were mixed by many respondents suggested postop day one, based on experience.

In the absence of more defined data, the current evidence/opinions are interpreted to suggest stating VTE chemoprophylaxis postoperative day one after spine surgery. However, this needs to be assessed based on individual situations and balanced by mixed suggestion of at least some evidence of increased risk of epidural hematoma.

Jonathan N. Grauer, Jeremy L. Fogelson

References

103. Bohl DD, Webb ML, Lukasiwicz AM, Samuel AM, Basques BA, Ahn J, Singh K, Vaccaro AR, Grauer JN. Timing of Complications After Spinal Fusion Surgery. *Spine (Phila Pa 1976)*. 2015 Oct 1;40(19):1527-35.
104. Adeeb N, Hattab T, Savardekar A, Jumah F, Griessenauer CJ, Musmar B, Adeeb A, Trosclair K, Guthikonda B. Venous Thromboembolism Prophylaxis in Elective Neurosurgery: A Survey of Board-Certified Neurosurgeons in the United States and Updated Literature Review. *World Neurosurg*. 2021 Jun;150:e631-8.
105. Glotzbecker MP, Bono CM, Harris MB, Brick G, Heary RF, Wood KB. Surgeon practices regarding postoperative thromboembolic prophylaxis after high-risk spinal surgery. *Spine (Phila Pa 1976)*. 2008 Dec 15;33(26):2915-21.
106. Kiguchi MM, Schobel H, TenEyck E, Earls B, Pan-Chen S, Freedman E, Ives AL, Rungkitwattanakul D, Mo F, Woo EY. The risks and benefits of early venous thromboembolism prophylaxis after elective spinal surgery: A single-center experience. *J Perioper Pract*. 2021 Jul 23;17504589211002070.
107. Zeeshan M, Khan M, O'Keefe T, Pollack N, Hamidi M, Kulvatunyou N, Sakran JV, Gries L, Joseph B. Optimal timing of initiation of thromboprophylaxis in spine trauma managed operatively: A nationwide propensity-matched analysis of trauma quality improvement program. *J Trauma Acute Care Surg*. 2018 Aug;85(2):387-92.
108. Dhillon ES, Khanna R, Cloney M, Roberts H, Cybulski GR, Koski TR, Smith ZA, Dahdaleh NS. Timing and risks of chemoprophylaxis after spinal surgery: a single-center experience with 6869 consecutive patients. *J Neurosurg Spine*. 2017 Dec;27(6):681-93.
109. Cox JB, Weaver KJ, Neal DW, Jacob RP, Hoh DJ. Decreased incidence of venous thromboembolism after spine surgery with early multimodal prophylaxis: Clinical article. *J Neurosurg Spine*. 2014 Oct;21(4):677-84.
110. McLynn RP, Diaz-Collado PJ, Ottesen TD, Ondeck NT, Cui JJ, Bovonratwet P, Shultz BN, Grauer JN. Risk factors and pharmacologic prophylaxis for venous thromboembolism in elective spine surgery. *Spine J*. 2018 Jun;18(6):970-8.

5 - If VTE prophylaxis is to be administered, does the number of levels, and/or the anatomical location, and/or surgical approach (i.e., minimally invasive) influence the choice of VTE prophylaxis for patients undergoing spinal surgery?

Recommendation: There is some evidence suggesting that chemoprophylaxis should be considered in patients undergoing multi-level lumbar spine surgery, especially when performed through an anterior approach.

Strength of Recommendation: Limited.

Delegates vote: Agree 96.30% Disagree 0.00% Abstain 3.70% (Strong Consensus).

Rationale: There are many thromboprophylaxis methods used in spinal surgery, including elastic compression stockings (CS), pneumatic sequential compression devices (SCD), low-molecular-weight heparin (LMWH), heparin, and inferior vena cava (IVC) filters. However, the lack of clear clinical evidence of superiority has led to a wide variability in surgeon preference compared to those for other orthopaedic procedures, such as lower extremity trauma or knee/hip arthroplasty, where the clinical evidence is more robust¹¹¹. The American College of Chest Physicians (ACCP) recommended against routine prophylaxis for elective spinal surgeries in patients with no significant risk factors, and a combination of mechanical and chemoprophylaxis in patients with multiple risk factors¹¹².

One obvious confounding variable is that multi-level surgeries have a longer operative time, which is a known independent risk factor for venous thromboembolism (VTE)¹¹³⁻¹¹⁵. Despite this, in a prospective trial comparing the effect of SCD on 100 patients undergoing single level anterior cervical corpectomy and fusion (ACCF) to 100 patients undergoing multilevel ACCF/posterior fusion, Epstein et al., found one VTE event in the former group and 7 in the latter group¹¹⁶. Additionally, in a case-control study, Hohl et al., observed that when treated with mechanical compression alone, patients undergoing elective degenerative thoracolumbar surgery involving ≥ 5 segment fusion exhibited a 2.3% prevalence of pulmonary embolism (PE)¹¹⁷. Patients at high risk of VTE, namely those undergoing surgery on more than 5 segments, combined anterior-posterior approaches and ilio caval manipulation, have been observed to have a lowered rate (odds ratio [OR] 3.7) of PE when receiving IVC filter and post-operative chemoprophylaxis with LMWH^{118,119}. A few other studies have found that placement of IVC in high-risk patients was protective against VTE¹²⁰⁻¹²².

In terms of anatomic location, Oda et al., found in a trial of 134 patients a higher incidence of venographic deep venous thrombosis (DVT) during lumbar surgery (26.5%) compared to cervical (5.6%) and thoracic (14.3%) surgeries. It is important to note that no patients in this cohort received any VTE prophylaxis, nor did any of the patients develop clinical signs of PE; all VTE events were detected by routine venography¹²³. Rokito et al., conducted a randomized control trial investigating the use of CS, CS + SCD, and SCD + warfarin in a study population of 329 patients undergoing major reconstructive spinal procedures in the cervical, thoracic, and/or lumbar spine. There was no benefit to using warfarin and that CS + SCD were adequate for most procedures regardless of spinal level being operated on¹²⁴. The reported rate of DVT after spine surgery, ranging from 0.6% - 6% is very low^{117,122,125-127}.

Anterior and combined anterior/posterior approaches are one of the high-risk factors for VTE according to the 7th ACCP venous thrombosis prevention guidelines¹¹². It becomes difficult to elucidate causality associated to these approach-specific risk factors from other high-risk patient factors. It is thought that the risk associated with anterior and anterior/posterior approaches is related to intraoperative manipulation of the iliac and great vessels^{118,119,122,128,129}. Oda et al., found a 15.5% incidence of asymptomatic DVT (by venography screening) after posterior spinal surgery without any prophylaxis¹²³. Dearborn et al., found in their retrospective cohort a 6.1% PE incidence in spine patients undergoing anterior and posterior approaches compared to a 0.5% in the posterior approach group¹³⁰. These patients had only mechanical prophylaxis. Pateder et al., conducted a similar study with the addition of pharmacologic prophylaxis using warfarin, LMWH or heparin, according to availability and surgeon judgement. They observed a PE incidence of 3% with anterior and combined approaches, and 0.65% with posterior approaches. The apparent decrease in anterior incidence compared to Dearborn et al., was attributed to the chemoprophylaxis preventing thrombi formation after

endothelial injury to the great vessels¹²⁹. This mechanism is supported by the posterior approach incidence of 0.65%, similar to Dearborn et al., suggesting a posterior approach may not equally benefit from the added pharmacologic prophylaxis. Interestingly, Pateder et al., also noted that right-side anterior approaches, which require manipulation of the vena cava, had a higher rate of PE compared to left-side approaches, which require manipulation of the aorta (13.3% vs. 2.3%)¹²⁹.

Adding to the debate, McLynn et al., compared the National Surgical Quality Improvement Program (NSQIP) database to a retrospective cohort and found conflicting evidence for the necessity of prophylaxis, demonstrating no associated increased risk of VTE with multi-level procedures or due to a specific surgical approach¹²⁵. They also did not find a reduction in VTE with pharmacologic prophylaxis (relative risk [RR] = 1.32 p = 0.421) but did find an increase in the occurrence of hematoma requiring reoperation with prophylaxis compared to without (0.62% vs. 0.08%; RR = 7.80, p = 0.020). Pendharker et al., found a decreased rate of VTE in microscopic lumbar discectomy group in a study on 42,025 patients which was compared outcomes of lumbar macro discectomy versus micro discectomy¹³¹.

The risk associated with undue pharmacologic VTE prophylaxis is excessive bleeding, specifically epidural hematomas, due to the potential for devastating neurologic injury. Thus, the risk of possible VTE needs to be weighed against the risk of administration of VTE prophylaxis to patients undergoing spine procedures.

Jose A. Canseco, Arun P. Kanhere, Ana Castel-Oñate, Alexander R. Vaccaro

References

111. Glotzbecker MP, Bono CM, Harris MB, Brick G, Heary RF, Wood KB. Surgeon practices regarding postoperative thromboembolic prophylaxis after high-risk spinal surgery. *Spine (Phila Pa 1976)*. 2008 Dec 15;33(26):2915-21.
112. Hirsh J, Guyatt G, Albers GW, Schünemann HJ. Proceedings of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: evidence-based guidelines. *Chest*. 2004 Sep;126(3)(Suppl):172S-696S.
113. Zigler JE, Ohnmeiss DD. Comparison of 2-Level Versus 1-Level Total Disc Replacement: Results From a Prospective FDA-Regulated Trial. *SAS J*. 2008 Sep 1; 2(3):140-4.
114. Kim JYS, Khavanin N, Rambachan A, McCarthy RJ, Mlodinow AS, De Oliveria GS Jr, Stock MC, Gust MJ, Mahvi DM. Surgical duration and risk of venous thromboembolism. *JAMA Surg*. 2015 Feb;150(2):110-7.
115. Kim BD, Hsu WK, De Oliveira GS Jr, Saha S, Kim JYS. Operative duration as an independent risk factor for postoperative complications in single-level lumbar fusion: an analysis of 4588 surgical cases. *Spine (Phila Pa 1976)*. 2014 Mar 15;39(6): 510-20.
116. Epstein NE. Intermittent pneumatic compression stocking prophylaxis against deep venous thrombosis in anterior cervical spinal surgery: a prospective efficacy study in 200 patients and literature review. *Spine (Phila Pa 1976)*. 2005 Nov 15; 30(22):2538-43.
117. Hohl JB, Lee JY, Rayappa SP, Nabb CE, Devin CJ, Kang JD, Ward WT, Donaldson WF 3rd. Prevalence of venous thromboembolic events after elective major thoracolumbar degenerative spine surgery. *J Spinal Disord Tech*. 2015 Jun; 28(5):E310-5.
118. McClendon J Jr, O'Shaughnessy BA, Smith TR, Sugrue PA, Halpin RJ, Morasch M, Koski T, Ondra SL. Comprehensive assessment of prophylactic preoperative inferior vena cava filters for major spinal reconstruction in adults. *Spine (Phila Pa 1976)*. 2012 Jun 1;37(13):1122-9.
119. McClendon J Jr, Smith TR, O'Shaughnessy BA, Sugrue PA, Thompson SE, Koski TR. Time to Event Analysis for the Development of Venous Thromboembolism After Spinal Fusion ≥ 5 Levels. *World Neurosurg*. 2015 Sep;84(3):826-33.

- 120.** Leon L, Rodriguez H, Tawk RG, Ondra SL, Labropoulos N, Morasch MD. The prophylactic use of inferior vena cava filters in patients undergoing high-risk spinal surgery. *Ann Vasc Surg.* 2005 May;19(3):442-7.
- 121.** Rosner MK, Kuklo TR, Tawk R, Moquin R, Ondra SL. Prophylactic placement of an inferior vena cava filter in high-risk patients undergoing spinal reconstruction. *Neurosurg Focus.* 2004 Oct 15;17(4):E6.
- 122.** Glotzbecker MP, Bono CM, Wood KB, Harris MB. Thromboembolic disease in spinal surgery: a systematic review. *Spine (Phila Pa 1976).* 2009 Feb 1;34(3):291-303.
- 123.** Oda T, Fuji T, Kato Y, Fujita S, Kanemitsu N. Deep venous thrombosis after posterior spinal surgery. *Spine (Phila Pa 1976).* 2000 Nov 15;25(22):2962-7.
- 124.** Rokito SE, Schwartz MC, Neuwirth MG. Deep vein thrombosis after major reconstructive spinal surgery. *Spine (Phila Pa 1976).* 1996 Apr 1;21(7):853-8, discussion :859.
- 125.** McLynn RP, Diaz-Collado PJ, Ottesen TD, Ondeck NT, Cui JJ, Bovonratwet P, Shultz BN, Grauer JN. Risk factors and pharmacologic prophylaxis for venous thromboembolism in elective spine surgery. *Spine J.* 2018 Jun;18(6):970-8.
- 126.** Smith SF, Simpson JM, Sekhon LHS. Prophylaxis for deep venous thrombosis in neurosurgical oncology: review of 2779 admissions over a 9-year period. *Neurosurg Focus.* 2004 Oct 15;17(4):E4.
- 127.** Du W, Zhao C, Wang J, Liu J, Shen B, Zheng Y. Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery. *J Orthop Surg Res.* 2015 May 23;10:78.
- 128.** Platzer P, Thalhammer G, Jandl M, Obradovic A, Benesch T, Vecsei V, Gaebler C. Thromboembolic complications after spinal surgery in trauma patients. *Acta Orthop.* 2006 Oct;77(5):755-60.
- 129.** Pateder DB, Gonzales RA, Kebaish KM, Antezana DF, Cohen DB, Chang JY, Kostuik JP. Pulmonary embolism after adult spinal deformity surgery. *Spine (Phila Pa 1976).* 2008 Feb 1;33(3):301-5.
- 130.** Dearborn JT, Hu SS, Tribus CB, Bradford DS. Thromboembolic complications after major thoracolumbar spine surgery. *Spine (Phila Pa 1976).* 1999 Jul 15; 24(14):1471-6.
- 131.** Pendharkar AV, Rezaii PG, Ho AL, Sussman ES, Purger DA, Veeravagu A, Ratliff JK, Desai AM. Propensity-matched comparison of outcomes and cost after macroscopic and microscopic lumbar discectomy using a national longitudinal database. *Neurosurg Focus.* 2018 May;44(5):E12.

6 - Is aspirin a viable chemoprophylaxis for VTE in patients undergoing spine surgery?

Response/Recommendation: While aspirin (ASA) may reduce venous thromboembolism (VTE) after orthopaedic procedures, there are no high-quality studies addressing this issue in patients undergoing spine surgery. We recommend surgeons weigh the potential benefits of chemoprophylaxis with known risks of increased bleeding.

Strength of Recommendation: Consensus.

Delegates vote: Agree 96.43% Disagree 0.00% Abstain 3.57% (Strong Consensus).

Rationale: VTE following orthopaedic procedures is a feared complication as it may lead to fatal pulmonary embolism (PE). The incidence of VTE following spine surgery is not well established with published rates varying from 0.3 - 31%¹³²⁻¹³⁸. Currently, no specific protocol exists for VTE prophylaxis in patients undergoing spine surgery likely due to the heterogeneity of cases performed by spine surgeons. Another reason is that VTE chemoprophylaxis in spine surgery may increase the risk of bleeding and hematoma formation, which can result in cord impingement and paralysis¹³⁹. Although the efficacy of ASA chemoprophylaxis following hip and knee joint arthroplasty is robust¹⁴⁰⁻¹⁴⁴, evidence in spine surgery is extremely limited. Previous studies are heterogeneous to allow drawing strong conclusions regarding the use of ASA for VTE prevention.

The only prospective deep venous thrombosis (DVT) chemoprophylaxis study in spine surgery found no incidence of acute DVT in 117 patients who underwent posterior lumbar

spine fusion and were treated with 600 mg ASA twice a day (*bis in die* [BID])¹⁴⁵.

Another study, retrospective, evaluated two cohorts consisting of no prophylaxis vs. 150 mg ASA daily for VTE prophylaxis in patients undergoing spine surgery. The no prophylaxis group consisted of 697 procedures, 554 of these were described as laminotomies, decompressions, or disc enucleations, and the remaining 143 were posterolateral spinal fusions. This group has two cases of DVT and no PE for an overall VTE rate of 0.29%. The ASA prophylaxis group consisted of 414 procedures, 272 of these were non-fusion, as described previously and the remaining 142 were fusions. This group had one case of DVT and no cases of PE for a VTE occurrence of 0.24%. Thus, no difference was observed in the rates of VTE when prophylactic ASA was used¹⁴⁶.

A retrospective study of 637 patients who underwent surgery for spinal metastasis were given various VTE chemoprophylaxis starting 48 hours after surgery including low-molecular-weight heparin (LMWH), subcutaneous heparin, ASA, and warfarin. Symptomatic VTE developed in 11% of the patients that used any chemoprophylaxis and in 11% who received no chemoprophylaxis¹⁴⁷.

A retrospective review of a prospectively collected data on 200 patients who underwent anterior lumbar interbody fusion (ALIF) were given LMWH and tinzaparin the evening before surgery and then daily for 3 to 5 days while inpatient, and then ASA daily for 4 weeks on an outpatient basis. No VTE or bleeding occurred in any of these 200 patients¹⁴⁸.

Lastly, a retrospective study of 83,839 patients who underwent anterior cervical discectomy and fusion (ACDF), or posterior lumbar fusion (PLF) were given either ASA, regular heparin, or LMWH on the day of surgery. About 1,872 patients (2.23%) received ASA. No difference was found in the incidence of VTE between these groups. However, patients receiving ASA had increased odds of requiring a blood transfusion (1.48 [1.17 - 1.86])¹⁴⁹.

Conclusion: There is a dearth of studies investigating the use of ASA as a VTE prophylaxis in patients undergoing spine surgery. The studies that exist are low in quality and are not conclusive. Although ASA has been shown to be effective for prevention of VTE following other orthopaedic procedures, its efficacy as a VTE prophylaxis in patients undergoing spine surgery remains unproven.

Nicholas M. Siegel, Mark Lambrechts, Chadi Tannoury,
Alexander R. Vaccaro

References

- 132.** Catre MG. Anticoagulation in spinal surgery. A critical review of the literature. *Can J Surg.* 1997 Dec;40(6):413-9.
- 133.** Ferree BA. Deep venous thrombosis following lumbar laminotomy and laminectomy. *Orthopedics.* 1994 Jan;17(1):35-8.
- 134.** Ferree BA, Stern PJ, Jolson RS, Roberts JM 5th, Kahn A 3rd. Deep venous thrombosis after spinal surgery. *Spine (Phila Pa 1976).* 1993 Mar 1;18(3):315-9.
- 135.** Ferree BA, Wright AM. Deep venous thrombosis following posterior lumbar spinal surgery. *Spine (Phila Pa 1976).* 1993 Jun 15;18(8):1079-82.
- 136.** Leon L, Rodriguez H, Tawk RG, Ondra SL, Labropoulos N, Morasch MD. The prophylactic use of inferior vena cava filters in patients undergoing high-risk spinal surgery. *Ann Vasc Surg.* 2005 May;19(3):442-7.

- 137.** Oda T, Fuji T, Kato Y, Fujita S, Kanemitsu N. Deep venous thrombosis after posterior spinal surgery. *Spine (Phila Pa 1976)*. 2000 Nov 15;25(22):2962-7.
- 138.** Rokito SE, Schwartz MC, Neuwirth MG. Deep vein thrombosis after major reconstructive spinal surgery. *Spine (Phila Pa 1976)*. 1996 Apr 1;21(7):853-8, discussion :859.
- 139.** Yi S, Yoon DH, Kim KN, Kim SH, Shin HC. Postoperative spinal epidural hematoma: risk factor and clinical outcome. *Yonsei Med J*. 2006 Jun 30;47(3):326-32.
- 140.** Hood BR, Cowen ME, Zheng HT, Hughes RE, Singal B, Hallstrom BR. Association of Aspirin With Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty Compared With Other Anticoagulants: A Noninferiority Analysis. *JAMA Surg*. 2019 Jan 1;154(1):65-72.
- 141.** Farey JE, An VVG, Sidhu V, Karunaratne S, Harris IA. Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis. *Orthop Traumatol Surg Res*. 2021 Feb;107(1):102606.
- 142.** Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, Pelet S, Fisher W, Belzile E, Dolan S, Crowther M, Bohm E, MacDonald SJ, Gofton W, Kim P, Zukor D, Pleasance S, Andreou P, Doucette S, Theriault C, Abianui A, Carrier M, Kovacs MJ, Rodger MA, Coyle D, Wells PS, Vendittoli PA. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. *N Engl J Med*. 2018 Feb 22;378(8):699-707.
- 143.** Xu J, Kanagaratnam A, Cao JY, Chaggar GS, Bruce W. A comparison of aspirin against rivaroxaban for venous thromboembolism prophylaxis after hip or knee arthroplasty: A meta-analysis. *J Orthop Surg (Hong Kong)*. 2020 Jan-Apr;28(1):2309499019896024.
- 144.** Wilson DGG, Poole WEC, Chauhan SK, Rogers BA. Systematic review of aspirin for thromboprophylaxis in modern elective total hip and knee arthroplasty. *Bone Joint J*. 2016 Aug;98-B(8):1056-61.
- 145.** Nelson LD Jr, Montgomery SP, Dameron TB Jr, Nelson RB. Deep vein thrombosis in lumbar spinal fusion: a prospective study of antiembolic and pneumatic compression stockings. *J South Orthop Assoc*. 1996 Fall;5(3):181-4.
- 146.** Nicol M, Sun Y, Craig N, Wardlaw D. Incidence of thromboembolic complications in lumbar spinal surgery in 1,111 patients. *Eur Spine J*. 2009 Oct;18(10):1548-52.
- 147.** Groot OQ, Ogink PT, Paulino Pereira NR, Ferrone ML, Harris MB, Lozano-Calderon SA, Schoenfeld AJ, Schwab JH. High Risk of Symptomatic Venous Thromboembolism After Surgery for Spine Metastatic Bone Lesions: A Retrospective Study. *Clin Orthop Relat Res*. 2019 Jul;477(7):1674-86.
- 148.** Vint H, Mawdsley MJ, Coe C, Jensen CD, Kasis AG. The Incidence of Venous Thromboembolism in Patients Undergoing Anterior Lumbar Interbody Fusion: A Proposed Thromboprophylactic Regime. *Int J Spine Surg*. 2021 Apr;15(2):348-52.
- 149.** Fiasconaro M, Poeran J, Liu J, Wilson LA, Memtsoudis SG. Venous thromboembolism and prophylaxis therapy after elective spine surgery: a population-based study. *Can J Anaesth*. 2021 Mar;68(3):345-57.

7 - What is the optimal protocol for management of patients who are on aspirin for a non-spine related disorder prior to spine surgery?

Response/Recommendation: Prior to spine surgery, low dose-aspirin (LD-ASA) (81 mg - 500 mg) used for primary and secondary cardiovascular prevention, can be stopped for one to three days. For ASA doses > 1 g per day, ASA should be stopped for at least seven days prior to surgery. However, in patients with extensive cardiac history, it is reasonable to maintain LD-ASA (81 mg) throughout spine surgery.

Strength of the Recommendation: Moderate.

Delegates vote: Agree 89.29% Disagree 10.71% Abstain 0.00% (Strong Consensus).

Rationale: ASA is commonly used for patients with cardiovascular disease. ASA irreversibly inhibits platelet aggregation, with platelets typically requiring seven to ten days to fully regenerate¹⁵⁰. ASA discontinuation prior to non-cardiac surgery has been associated with a rebound hypercoagulation effect and a 5- to 10-fold increase in the mortality rate related to acute myocardial infarction^{151,152}.

Park et al., evaluated the timing of ASA cessation prior to one- or two-level lumbar fusion (three to seven days vs. seven to ten days prior to surgery)¹⁵³. They evaluated three groups: ASA naïve patients vs. patients who stopped ASA three to seven days pre-surgery, vs. patients who stopped ASA seven to ten days pre-surgery¹⁵³. Patients who stopped ASA three to seven days prior to surgery experienced more surgical drainage and longer time of surgical drainage compared to the other two groups¹⁵³. They also found that if ASA was stopped more than seven days before spine surgery, there was no significant difference in bleeding risk compared to the other two groups¹⁵³. On the other hand, Kang et al., compared two groups of patients undergoing spinal fusion: ASA naïve patients vs. patients who stopped LD-ASA (100 mg) at least seven days prior to surgery¹⁵⁴. The ASA group experienced significantly increased rates of postoperative hemorrhage, higher transfusion requirements, and wound complications even when ASA was stopped at least seven days prior to surgery¹⁵⁴. Nonetheless, they recommended stopping LD-ASA seven days preoperatively¹⁵⁴. In another study, Park et al., divided patients who underwent two or more level lumbar fusions into three groups: ASA naïve (group I, 38 patients) vs. patients who stopped ASA one week prior to surgery (group II, 38 patients), vs. patients who continued LD-ASA throughout surgery (group III, 30 patients)¹⁵⁵. They found that LD-ASA significantly increased bleeding for groups II and III compared to ASA naïve patients¹⁵⁵. Furthermore, the additional utilization of non-steroidal anti-inflammatory (NSAID) medication was a confounding variable that increased perioperative blood loss in all three groups¹⁵⁵. Therefore, it is also suggested to stop NSAID in the perioperative phase.

On the other hand, Cuellar et al., retrospectively analyzed 200 patients with cardiac stents who were randomized to either a group that underwent spine surgery while taking ASA (81 mg or 325 mg; 100 patients) or a group that stopped ASA five days prior to spine surgery (100 patients)¹⁵⁶. They demonstrated that patients who did not stop ASA had shorter length of hospitalization, reduced operative time, similar blood loss, and comparable overall complication and readmission rates to the patients who stopped ASA five days before surgery¹⁵⁶. Importantly, there was no major increase in the rate of epidural hematoma formation in patients who continued ASA¹⁵⁶. Similarly, Soleman et al., conducted a retrospective analysis of 102 patients undergoing non-instrumented lumbar decompression surgery¹⁵⁷. They compared perioperative risks of bleeding and cardiovascular complications of patients on daily ASA 100 mg (40 patients) vs. a control group who stopped ASA (62 patients)¹⁵⁷. They demonstrated that ASA continuation was safe, and did not lead to higher risk of morbidity, perioperative blood loss, surgical time, or length of hospitalization¹⁵⁷. Nevertheless, one patient remaining on LD-ASA developed an epidural hematoma, resulting in irreversible paralysis¹⁵⁷. This complication challenges the safety of continuing perioperative ASA in spine surgery.

More recently, the American Society of Regional Anesthesia (ASRA) published its guidelines on managing anti-coagulation in patients undergoing interventional spine and

pain procedures. The ASRA concluded that surgery can be performed safely after ASA cessation as follows: after 12 hours if LD-ASA (< 1 g) is used for secondary prevention, and after three days if ASA is used for primary prevention¹⁵⁸. This cessation time is extended to one week preoperatively for ASA doses greater than 1 g per day¹⁵⁸. The ASRA also suggested that 81 mg ASA can be reasonably maintained in patients with extensive cardiac history (i.e., drug eluting stents), with its potential benefits outweighing the risk of major surgical bleeding¹⁵⁸. This recommendation was supported by other recent studies, suggesting the safety of continuing antiplatelet drugs throughout spine surgery^{159,160}.

Despite the mixed and contrasting data, prophylactic LD-ASA (81 mg - 500 mg) can typically be stopped for one to three days prior to spine surgery, but for one week if the ASA dose is greater than 1 g per day. In patients with extensive cardiac history, it is reasonable to maintain LD-ASA (81 mg) throughout spine surgery.

Chadi Tannoury, Ryan M. Sutton

References

150. Park HJ, Kwon KY, Woo JH. Comparison of blood loss according to use of aspirin in lumbar fusion patients. *Eur Spine J*. 2014 Aug;23(8):1777-82.
151. Chassot PG, Marcucci C, Delabays A, Spahn DR. Perioperative antiplatelet therapy. *Am Fam Physician*. 2010 Dec 15;82(12):1484-9.
152. Gerstein NS, Schulman PM, Gerstein WH, Petersen TR, Tawil I. Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome. *Ann Surg*. 2012 May;255(5):811-9.
153. Park JH, Ahn Y, Choi BS, Choi KT, Lee K, Kim SH, Roh SW. Antithrombotic effects of aspirin on 1- or 2-level lumbar spinal fusion surgery: a comparison between 2 groups discontinuing aspirin use before and after 7 days prior to surgery. *Spine (Phila Pa 1976)*. 2013 Aug 15;38(18):1561-5.
154. Kang SB, Cho KJ, Moon KH, Jung JH, Jung SJ. Does low-dose aspirin increase blood loss after spinal fusion surgery? *Spine J*. 2011 Apr;11(4):303-7.
155. Park JH, Ahn Y, Choi BS, Choi KT, Lee K, Kim SH, Roh SW. Antithrombotic effects of aspirin on 1- or 2-level lumbar spinal fusion surgery: a comparison between 2 groups discontinuing aspirin use before and after 7 days prior to surgery. *Spine (Phila Pa 1976)*. 2013 Aug 15;38(18):1561-5.
156. Cuellar JM, Petrizzo A, Vaswani R, Goldstein JA, Bendo JA. Does aspirin administration increase perioperative morbidity in patients with cardiac stents undergoing spinal surgery? *Spine (Phila Pa 1976)*. 2015 May 1;40(9):629-35.
157. Soleman J, Baumgarten P, Perrig WN, Fandino J, Fathi AR. Non-instrumented extradural lumbar spine surgery under low-dose acetylsalicylic acid: a comparative risk analysis study. *Eur Spine J*. 2016 Mar;25(3):732-9.
158. Narouze S, Benzon HT, Provenzano D, Buvanendran A, De Andres J, Deer T, Rauck R, Huntoon MA. *Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain*. *Reg Anesth Pain Med*. 2018 Apr;43(3):225-62.
159. Shin WS, Ahn DK, Lee JS, Yoo IS, Lee HY. The Influence of Antiplatelet Drug Medication on Spine Surgery. *Clin Orthop Surg*. 2018 Sep;10(3):380-4.
160. Zhang C, Wang G, Liu X, Li Y, Sun J. Safety of continuing aspirin therapy during spinal surgery: A systematic review and meta-analysis. *Medicine (Baltimore)*. 2017 Nov;96(46):e8603.

8 - What is the optimal protocol for management of patients who are being treated with warfarin for a non-spine related disorder prior to spine surgery?

Response/Recommendation: Warfarin (Coumadin) should be discontinued at least 5 days before spine surgery, and the international normalized ratio (INR) goal should be 1.2 or less.

Strength of the Recommendation: Moderate.

Delegates vote: Agree 92.86% Disagree 3.57% Abstain 3.57% (Strong Consensus).

Rationale: Warfarin, a vitamin K antagonist (36 - 42 hours half-life), reduces the function of clotting factors II, VII, IX, and X by blocking the vitamin K epoxide reductase enzyme¹⁶¹. It is a commonly used anticoagulant for treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE), and prevention of cerebrovascular accidents in patients with atrial fibrillation, valvular heart disease, or artificial heart valves. Perioperative continuation of warfarin can be associated with increased risk of bleeding¹⁶². Rokito et al., reported that in patients undergoing major reconstructive spinal surgery, the perioperative use of warfarin can be associated with major blood loss (> 800 mL), while adding no benefit in DVT prevention compared to the use of compression stocking and sequential compression devices¹⁶³. Benzon et al., studied the remaining anticoagulation effect of warfarin five days after its discontinuation. In the majority of patients (n = 21), the international normalized ratio (INR) normalized to less than 1.2, which was considered adequate for safe neuraxial procedures¹⁶⁴. A small number of patients (n = 2) had INR values of 1.3 or 1.4. However, the safety of this INR range for neuraxial injections was considered inconclusive¹⁶⁴. Narouze et al., and the American Society of Regional Anesthesia (ASRA) published guidelines recommending stopping warfarin five to six days before interventional spine and pain procedures, with a goal INR of 1.4 or less¹⁶⁵. While most available data suggest withholding warfarin for a minimum of five preoperative days to be reasonably safe in patients undergoing spinal surgeries, there is concern for increased operative blood loss even after seven days of warfarin discontinuation. Young et al., evaluated 263 patients undergoing elective lumbar spine surgery including laminectomy with and without instrumented posterolateral fusion¹⁶⁶. All patients on warfarin had their anticoagulation stopped seven days prior to surgery¹⁶⁶. They noted that patients on warfarin (n = 13) had significant increase in intraoperative blood loss (839 mL vs. 441 mL) and postoperative blood transfusions (23% vs. 7.4%, p = 0.04) compared to patients not on warfarin (n = 250)¹⁶⁶. Despite the limited data on neurologic and spinal surgery, warfarin discontinuation is recommended for a minimum of five preoperative days. Additionally, while a goal INR of 1.4 or less is acceptable, a more conservative range of 1.2 or less is adequate for safe spinal surgeries.

Chadi Tannoury, Ryan M. Sutton

References

161. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012 Feb;141(2)(Suppl):e44S-88S.
162. Coumadin. Princeton, NJ: Bristol-Myers Squibb Company; 1954.
163. Rokito SE, Schwartz MC, Neuwirth MG. Deep vein thrombosis after major reconstructive spinal surgery. *Spine (Phila Pa 1976)*. 1996 Apr 1;21(7):853-8, discussion :859.
164. Benzon HT, Asher Y, Kendall MC, Vida L, McCarthy RJ, Green D. Clotting-factor concentrations 5 days after discontinuation of warfarin. *Reg Anesth Pain Med*. 2018 Aug;43(6):616-20.
165. Narouze S, Benzon HT, Provenzano D, Buvanendran A, De Andres J, Deer T, Rauck R, Huntoon MA. *Interventional Spine and Pain Procedures in Patients on*

Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. *Reg Anesth Pain Med.* 2018 Apr;43(3):225-62.

166. Young EY, Ahmadinia K, Bajwa N, Ahn NU. Does chronic warfarin cause increased blood loss and transfusion during lumbar spinal surgery? *Spine J.* 2013 Oct;13(10):1253-8.

9 - In patients on anticoagulants for a non-spine disorder, is perioperative bridging therapy necessary following cessation of anticoagulation prior to spine surgery?

Response/Recommendation: Perioperative bridging anticoagulation therapy is not superior to placebo in preventing thromboembolic events following cessation of anticoagulation prior to spine surgery. Additionally, bridging anticoagulation therapy can be associated with higher risk of major bleeding.

If a bridging therapy is contemplated in high-risk patients, and at the discretion of the treating physician, unfractionated heparin and low-molecular-weight heparin (LMWH) are reasonable options.

Strength of the Recommendation: Limited.

Delegates vote: Agree 89.29% Disagree 3.57% Abstain 7.14% (Strong Consensus).

Rationale: Preoperative discontinuation of anticoagulation is commonly practiced mitigating the risks of bleeding and the formation of neuraxial hematoma¹⁶⁷⁻¹⁷⁰. However, anticoagulant cessation may promote thromboembolic events in high-risk patients with valvular heart disease, atrial fibrillation, ischemic stroke, or venous thromboembolism (VTE).

The concept of bridging anticoagulation therapy was therefore hypothesized to minimize the risk of thromboembolic events in the perioperative period after discontinuation of anticoagulation. In a randomized double blinded study, Douketis et al., reported comparable risk of arterial thromboembolic events with or without the use of perioperative bridging therapy LMWH vs. placebo, following cessation of warfarin in patients with atrial fibrillation¹⁷¹. They recommended against the use of bridging therapy due to a lack of superiority in preventing thromboembolic events, and the associated risk of major bleeding¹⁷¹. This study was not specific to spine surgery, however, and excluded patients with a history of mechanical heart valve, stroke, or VTE within 12 weeks prior to surgery¹⁷¹.

In another study, Steinberg et al., reported a higher rate of bleeding if bridging anticoagulation therapy (LMWH or unfractionated heparin [UFH]) was implemented during perioperative interruption of anticoagulation therapy (odds ratio [OR] = 3.84)¹⁷². As a result, they recommended against the use of routine bridging therapy¹⁷². This study was also not specific to patients undergoing spine surgery¹⁷². In 2009, the North American Spine Society (NASS) issued clinical guidelines for the use of antithrombotic therapy in spine surgery, and the published consensus did not support an ideal perioperative bridging anticoagulation therapy¹⁷³. The workgroup also suggested that the ideal time to withhold anticoagulation prior to surgery is unique to each drug's clearance half-life¹⁷³. If a bridging therapy is contemplated in high-risk patients, despite

the limited evidence, the workgroup suggested that either intravenous UFH or LMWH is a reasonable bridging anticoagulation agent following warfarin¹⁷³. They argued, however, that intravenous heparin is more controllable and predictable than LMWH¹⁷³. A bridging-intravenous-heparin-therapy should be stopped 4 - 6 hours (based on a half-life of 1 - 2 hours) prior to surgery and can be resumed 24 hours postoperatively^{169,174}. Alternatively, bridging enoxaparin should be stopped 24 hours (based on a half-life of 4 - 7 hours) prior to surgery and can be resumed 12 - 24 hours postoperatively¹⁶⁹.

In conclusion, despite the limited evidence related to spine surgery, perioperative bridging anticoagulation therapy is not superior to placebo in preventing thromboembolic events following cessation of anticoagulation prior to surgery. Additionally, bridging therapy can be associated with higher risk of major bleeding. If a bridging therapy is contemplated in high-risk patients, UFH and LMWH are reasonable options.

Chadi Tannoury, Ryan M. Sutton

References

167. Rokito SE, Schwartz MC, Neuwirth MG. Deep vein thrombosis after major reconstructive spinal surgery. *Spine (Phila Pa 1976).* 1996 Apr 1;21(7):853-8, discussion :859.
168. Coumadin. Princeton, NJ: Bristol-Myers Squibb Company; 1954.
169. Narouze S, Benzon HT, Provenzano D, Buvanendran A, De Andres J, Deer T, Rauck R, Huntoon MA. *Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain.* *Reg Anesth Pain Med.* 2018 Apr;43(3):225-62.
170. Young EY, Ahmadinia K, Bajwa N, Ahn NU. Does chronic warfarin cause increased blood loss and transfusion during lumbar spinal surgery? *Spine J.* 2013 Oct;13(10):1253-8.
171. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AGG, Hasselblad V, Ortel TL; BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. *N Engl J Med.* 2015 Aug 27;373(9):823-33.
172. Steinberg BA, Peterson ED, Kim S, Thomas L, Gersh BJ, Fonarow GC, Kowey PR, Mahaffey KW, Sherwood MW, Chang P, Piccini JP, Ansell J; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Investigators and Patients. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). *Circulation.* 2015 Feb 3;131(5):488-94.
173. Bono CM, Watters WC 3rd, Heggeness MH, Resnick DK, Shaffer WO, Baisden J, Ben-Galim P, Easa JE, Fernand R, Lamer T, Matz PG, Mendel RC, Patel RK, Reitman CA, Toton JF. An evidence-based clinical guideline for the use of antithrombotic therapies in spine surgery. *Spine J.* 2009 Dec;9(12):1046-51.
174. Horlocker TT, Vandermeulen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. *Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition).* *Reg Anesth Pain Med.* 2018 Apr;43(3):263-309.

10 - Do patients with spine trauma require routine VTE prophylaxis before and after surgery?

Response/Recommendation: Patients suffering from traumatic spine injury are at an increased risk for venous thromboembolism (VTE). Recommendations for VTE prophylaxis before and after surgery in spine trauma varies based on pertinent factors such as presence of spinal cord injury (SCI), segment of the spine involved and age.

Strength of Recommendation: Moderate.

Delegates vote: Agree 100.00% Disagree 0.00% Abstain 0.00% (Unanimous Strong Consensus).

Rationale: Understanding the use VTE prophylaxis in surgical spinal trauma is very important in clinical practice as it aids in surgical planning and management. The current literature is lacking in terms of a standard of practice and future research is warranted.

VTE which includes deep venous thrombosis (DVT), and pulmonary embolism (PE) is one the most common complications following major joint surgery, with an incidence between 2.9% and 3.7%¹⁷⁵. While there has been a focus on the incidence of VTE in other major orthopaedic procedures such as emergency hip fracture care and total hip/knee arthroplasty, there exists a gap in the literature in examining the incidence of VTE after spinal surgery. The range of VTE in spinal surgery ranges from 3% to 31% based on the patient population and diagnostic methodology^{176,177}. To date there is no clear consensus or standard of practice with regards to VTE prophylaxis in spinal trauma surgery. In a major study conducted by Glotzbecker et al., in 2008, 94 orthopaedic and neurological spine surgeons with established clinical interest and volume in spine trauma surgery responded to questions focused on varying issues that included the perceived risk of DVT, PE, postoperative epidural hematoma, preferred chemoprophylactic agents, the safe time point for initiation of chemoprophylaxis, and use of inferior vena cava (IVC) filters. The authors concluded that there is wide variability in practices regarding thromboprophylaxis in spinal trauma surgery, which likely occurred due to the paucity of scientific evidence in the literature^{178,179}.

VTE prophylaxis in spinal trauma surgery can be stratified based on the presence or absence of SCI. In patients without significant SCI, there is preservation of neurologic function with mobility of the extremities and decreased venous blood stasis. The reported incidence of VTE in patients with SCI has a wide range of 2% to 45.2%¹⁸⁰⁻¹⁸³. In a large population study of a total of 47,916 Taiwanese patients with SCI, the authors found a 2.5-fold increased risk of DVT and a 1.6-fold increased risk of PE when compared with controls¹⁸⁴. Also, in an analysis by Ploumis et al., the authors found that the prevalence of DVT was significantly lower in patients without SCI as compared to patients with SCI (odds ratio [OR] = 6.0; 95% confidence interval [CI] = 2.9 - 12.7). Furthermore, patients with an acute SCI who were receiving oral anticoagulants had significantly fewer episodes of PE (OR = 0.1; 95% CI = 0.01 to 0.63) than those who were not receiving oral anticoagulants. Starting thromboprophylaxis within the first two weeks after the injury resulted in significantly fewer DVT events than delayed initiation did (OR = 0.2; 95% CI = 0.1 to 0.4)¹⁸⁵. In spine trauma patients with associated SCI, the recommendation is to start VTE prophylaxis as early as possible and once it is deemed safe.

Risk factors for VTE in patients with SCI include increased age, obesity, flaccid paralysis, and cancer. Age as a risk factor is very important, several studies have shown that among patients with SCI, older patients are more likely to develop VTE^{186,187}. In a study

conducted by Jones T. et al., with a total of 16,240 SCI patients, the authors concluded that patients with age < 30 years had a lower risk of developing a thromboembolic event¹⁸⁸. The risk is greatest in the first three months post-injury. In elderly SCI patients, VTE prophylaxis should be administered rigorously pre- and post-operatively.

In addition to the presence or absence of SCI, the segment of the spine also plays an important role in deciding whether DVT prophylaxis should be administered before and after surgery. In another article by Ploumis et al., the authors surveyed twenty-five spine trauma surgeons pertaining to the management of VTE prophylaxis in patients with spine fractures (with and without concomitant SCI). It was concluded that in most surgical cases of cervical spine trauma with associated SCI and thoracolumbar spine trauma with or without SCI, postoperative VTE prophylaxis is necessary. However, postoperative VTE prophylaxis after cervical spine injuries without SCI was agreed not to be needed. VTE prophylaxis is recommended to be started as early as possible in SCI cases or any cases with surgical delay. The current recommendation is that pharmacologic VTE prophylaxis needs to be administered for at least three months post-injury¹⁸⁹.

Even though patients with spinal fractures are likely to receive VTE prophylaxis pre- and post-operatively, it has been shown in the literature that these patients still have a high rate of VTE when compared to patients undergoing elective spine surgery¹⁹⁰. One of the major reasons why many spine trauma surgeons may be reluctant to initiate VTE prophylaxis in the early stages of injury or even immediately after surgery is the possible increased risk of bleeding (especially epidural hematoma), neurologic and wound healing complications that may occur in certain patients^{191,192}. In a study by Kim DY et al., the authors analyzed 206 patients who underwent operative fixation for spine fractures. Forty-eight (23%) patients received early (< 48 hours) VTE prophylaxis, and 158 patients (76.7%) received late (> 48 hours) VTE prophylaxis. They found no difference in bleeding or neurologic complications between the two groups. In fact, none of the patients developed any bleeding complications in either group¹⁹³. In a more recent study by Zeeshan M. et al., the authors found similar results. A total of 3,554 patients were equally matched (1,772, early VTE prophylaxis; 1,772 late). Patients who received early VTE prophylaxis (< 48 hours) had decreased rates of DVT versus those who did not (2.1% vs. 10.8%, $p < 0.01$) in operative spinal trauma without increasing the risk of bleeding and mortality¹⁹⁴. Despite the research, there remain a wide variation in VTE prophylaxis for patients with spine trauma, based on the survey of spine surgeons^{178,179}.

In spinal trauma patients with concomitant SCI, low-molecular-weight heparin (LMWH) is more effective in preventing DVT than unfractionated heparin with fewer bleeding complications. Use of vitamin K antagonist was also more effective in preventing PE^{185,195}. Furthermore, according to Glotzbecker MP et al., the majority of surgeons surveyed selected LMWH as their agent of choice for chemoprophylaxis, with subcutaneous

heparin and coumadin as the second and third most common choices, respectively. In many cases in the post-operative period, chemical anticoagulation may be delayed due to concerns of bleeding or neurologic complications. Instead, IVC filters may be used in preventing a PE¹⁷⁹.

As previously mentioned, there is no clear standard of practice regarding the administration of VTE prophylaxis to patients suffering from spine trauma. There is a wide variability of practice regarding thromboprophylaxis in spinal trauma surgery. Further research examining the epidemiology of VTE in spinal surgery and the risks-benefit relationship of thromboprophylaxis is warranted.

Adwin Denasty, Addisu Mesfin

References

175. Bjørnarå BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. *J Bone Joint Surg Br.* 2006 Mar; 88(3):386-91.
176. Brambilla S, Ruosi C, La Maida GA, Caserta S. Prevention of venous thromboembolism in spinal surgery. *Eur Spine J.* 2004 Feb;13(1):1-8.
177. Glotzbecker MP, Bono CM, Wood KB, Harris MB. Thromboembolic disease in spinal surgery: a systematic review. *Spine (Phila Pa 1976).* 2009 Feb 1;34(3):291-303.
178. Bryson DJ, Uzoigwe CE, Braybrooke J. Thromboprophylaxis in spinal surgery: a survey. *J Orthop Surg Res.* 2012 Mar 29;7:14.
179. Glotzbecker MP, Bono CM, Harris MB, Brick G, Heary RF, Wood KB. Surgeon practices regarding postoperative thromboembolic prophylaxis after high-risk spinal surgery. *Spine (Phila Pa 1976).* 2008 Dec 15;33(26):2915-21.
180. Dhall SS, Hadley MN, Aarabi B, Gelb DE, Hurlbert RJ, Rozzelle CJ, Ryken TC, Theodore N, Walters BC. Deep venous thrombosis and thromboembolism in patients with cervical spinal cord injuries. *Neurosurgery.* 2013 Mar;72(Suppl 2):244-54.
181. Teasell RW, Hsieh JT, Aubut JAL, Eng JJ, Krassioukov A, Tu L; Spinal Cord Injury Rehabilitation Evidence Review Research Team. Venous thromboembolism after spinal cord injury. *Arch Phys Med Rehabil.* 2009 Feb;90(2):232-45.
182. Germing A, Schakrouf M, Lindstaedt M, Grewe P, Meindl R, Mügge A. Serial compression B-scan and Doppler sonography for the screening of deep venous thrombosis in patients with spinal cord injuries. *J Clin Ultrasound.* 2010 Jan;38(1):17-20.
183. Giorgi Pierfranceschi M, Donadini MP, Dentali F, Ageno W, Marazzi M, Bocchi R, Imberti D. The short- and long-term risk of venous thromboembolism in patients with acute spinal cord injury: a prospective cohort study. *Thromb Haemost.* 2013 Jan;109(1):34-8.
184. Chung WS, Lin CL, Chang SN, Chung HA, Sung FC, Kao CH. Increased risk of deep vein thrombosis and pulmonary thromboembolism in patients with spinal cord injury: a nationwide cohort prospective study. *Thromb Res.* 2014 Apr;133(4):579-84.
185. Ploumis A, Ponnappan RK, Maltenfort MG, Patel RX, Bessey JT, Albert TJ, Harrop JS, Fisher CG, Bono CM, Vaccaro AR. Thromboprophylaxis in patients with acute spinal injuries: an evidence-based analysis. *J Bone Joint Surg Am.* 2009 Nov; 91(11):2568-76.
186. Maung AA, Schuster KM, Kaplan LJ, Maerz LL, Davis KA. Risk of venous thromboembolism after spinal cord injury: not all levels are the same. *J Trauma.* 2011 Nov;71(5):1241-5.
187. Paffrath T, Wafaisade A, Lefering R, Simanski C, Bouillon B, Spanholtz T, Wutzler S, Maeglele M; Trauma Registry of DGU. Venous thromboembolism after severe trauma: incidence, risk factors and outcome. *Injury.* 2010 Jan;41(1):97-101.
188. Jones T, Ugalde V, Franks P, Zhou H, White RH. Venous thromboembolism after spinal cord injury: incidence, time course, and associated risk factors in 16,240 adults and children. *Arch Phys Med Rehabil.* 2005 Dec;86(12):2240-7.
189. Green D, Hartwig D, Chen D, Soltysik RC, Yarnold PR. Spinal Cord Injury Risk Assessment for Thromboembolism (SPIRATE Study). *Am J Phys Med Rehabil.* 2003 Dec;82(12):950-6.
190. Ploumis A, Ponnappan RK, Bessey JT, Patel R, Vaccaro AR. Thromboprophylaxis in spinal trauma surgery: consensus among spine trauma surgeons. *Spine J.* 2009 Jul;9(7):530-6.
191. Cloney MB, Yamaguchi JT, Dhillon ES, Hopkins B, Smith ZA, Koski TR, Dahdaleh NS. Venous thromboembolism events following spinal fractures: A single center experience. *Clin Neurol Neurosurg.* 2018 Nov;174:7-12.
192. Awad JN, Kebaish KM, Donigan J, Cohen DB, Kostuik JP. Analysis of the risk factors for the development of post-operative spinal epidural haematoma. *J Bone Joint Surg Br.* 2005 Sep;87(9):1248-52.
193. Kim DY, Kobayashi L, Chang D, Fortlage D, Coimbra R. Early pharmacological venous thromboembolism prophylaxis is safe after operative fixation of traumatic spine fractures. *Spine (Phila Pa 1976).* 2015 Mar 1;40(5):299-304.
194. Zeeshan M, Khan M, O'Keeffe T, Pollack N, Hamidi M, Kulvatunyou N, Sakran JV, Gries L, Joseph B. Optimal timing of initiation of thromboprophylaxis in spine trauma managed operatively: A nationwide propensity-matched analysis of trauma quality improvement program. *J Trauma Acute Care Surg.* 2018 Aug;85(2):387-92.
195. Green D, Rossi EC, Yao JS, Flinn WR, Spies SM. Deep vein thrombosis in spinal cord injury: effect of prophylaxis with calf compression, aspirin, and dipyridamole. *Paraplegia.* 1982 Aug;20(4):227-34.

11 - Does the presence of a dural tear influence the choice for VTE prophylaxis after spine surgery?

Response/Recommendation: Following spine surgery, the rate of venous thromboembolism (VTE) is significantly higher in patients with incidental durotomy (almost 1.5 times) compared to patients without. Therefore, in patients with dural tears post spine surgery, vigorous VTE prophylaxis therapies should be considered.

Strength of Recommendation: Limited.

Delegates vote: Agree 92.31% Disagree 3.85% Abstain 3.85% (Strong Consensus).

Rationale: Complications in spine surgery tend to occur in clusters as complex spinal pathologies lead to higher rate of successive undesirable events. Inadvertent dural tears during spine surgery are associated with increased in-hospital complications, health care burden, and readmission rates¹⁹⁶⁻¹⁹⁸. In a retrospective analysis, Alluri et al., found that VTE occurred in 1.3% of patients with a dural tear in contrast to 0.9% of patients without (odds ratio [OR] 1.46, $p < 0.001$)¹⁹⁹. Similarly, deep venous thrombosis (DVT) and pulmonary embolism (PE) occurred in 1% and 1% of patients with a dural tear and only in 0.7% and 0.7% of patients without durotomy (OR 1.36, $p = 0.03$ for DVT, OR 1.48, $p = 0.01$ for PE) respectively. This relationship was seen after matching specific demographic and comorbidity variables that were associated with VTE complications. Another observational cohort study by Durand et al., studied 86,212 patients who underwent spine surgery using the National Surgical Quality Improvement Program (NSQIP) dataset from 2012 to 2015²⁰⁰. The authors identified late-presenting dural tears (LPDT) using reoperation or readmission procedures defined by durotomy-specific Current Procedural Terminology (CPT) codes. After adjusting for patient and procedure-level factors, patients with LPDT had higher rates of surgical site infection (OR 2.54, $p < 0.0001$), wound disruption (OR 2.24, $p < 0.0001$), sepsis (OR 2.19, $p < 0.0001$), and VTE (OR 1.71, $p < 0.0001$). The authors suggested that predisposition of LPDT patients to wound infection and subsequent bacteremia may lead to higher risks of thromboembolic events²⁰¹. Although the underlying pathogenesis of VTE development in sepsis remains unclear, the etiology is thought to be the result of several factors associated with dural tears including immobility and activation of thrombo-inflammatory pathways²⁰²⁻²⁰⁴.

In another retrospective study using the Nationwide Inpatient Sample (NIS) database, Yoshihara et al., analyzed patient

outcomes after incidental durotomies in cervical spine surgery¹⁹⁶. In this study, the mean hospital stay was 1.4 days longer in patients with dural tears than in those without (4.6 vs. 3.0 days, $p < 0.001$). Rates of neurologic (3.0 vs. 0.4%, $p < 0.001$) complications (including transitory ischemic attack [TIA]/stroke) and PE (1.8 vs. 0.2%, $p < 0.001$) were significantly higher in the dural tear group.

Current postoperative managements of dural tears include subarachnoid lumbar drainage and/or postoperative bed rest, which can lead to extended immobilization and subsequent venous stasis, thereby increasing the odds of VTE^{196,198,205-207}. In a study investigating bedrest greater or less than 24 hours for incidental lumbar dural tear after laminectomy, there was a statistically significant increase in the incidence of medical complications in the bed rest group > 24 hours ($p = 0.0003$), which included greater rates of DVT (4.2 vs. 0%)²⁰⁸. However, this study was underpowered to statistically compare DVT rates.

In addition to postoperative immobility, increased rates of VTE in patients with dural tears may be attributed to increase in operative times. In a prospective cohort study of patients undergoing discectomy or laminectomy procedures, Smorgick et al., found that intraoperative repair of an incidental durotomy significantly increased operative duration (146 ± 59 vs. 110 ± 54 minutes; $p = 0.0025$)²⁰⁹. Another prospective, observational study by Weber et al., showed that an incidental dural tear prolonged surgical duration from 116 to 153 minutes ($p < 0.0001$) in patients undergoing elective spinal surgery for degenerative disorders of the cervical, thoracic, or lumbar spine²¹⁰. Inflammation and endothelial damage that occurs during surgery, in combination to immobility associated with prolonged surgical duration, can initiate the clotting cascade, and increase thrombus formation²¹¹⁻²¹⁵. It has been shown that ischemia and venous stasis, which occur during surgery, can also lead to DVT formation via the upregulation of P-selectin and local prothrombotic micro-particles^{216,217}. Few studies within the spine literature have investigated the direct effect of longer operative times on VTE risk²¹⁸. A prospective cohort study by Inoue et al., using indirect multi-detector computed tomography (MDCT) in 100 patients undergoing spine surgery found that operative duration was not significantly different in patients that did (87) and did not (13) develop VTE²¹⁹. However, this study was limited in cohort size and surgical durations. Schoenfeld et al., using the NSQIP dataset investigating 27,730 patients determined that operative time exceeding 261 minutes was associated with risk of developing DVT (OR: 3.1 95% confidence interval [CI]: 2.3 – 4.1) and PE (OR: 3.15 95% CI: 2.1 – 4.7); however, this operative time is significantly higher than those found in previous incidental durotomy studies²²⁰. Further studies focusing on the relationship between operating time and VTE risk in spine surgery are needed to determine a threshold duration of surgery.

The relationship between dural tears and VTE development is likely multifactorial and can be attributed to more complex pathology, longer operative duration, prolonged post-operative immobility, and risk for post-surgical infection. As such, a standardized approach to VTE prophylaxis in patients

undergoing elective spine surgery must consider these risk factors as well as preexisting individual risk factors and comorbidities to guide appropriate post-operative prophylaxis. Currently, risk stratification tools such as the Rogers and Caprini scores do not adequately factor in intraoperative variables, such as the complexity of the procedure, especially in the event of a dural tear^{221,222}. Data in dural tear studies were also limited to in-hospital events which may underestimate the true incidences of complications and mortality. In view of these limitations, clinicians should factor in identifiable preoperative and intraoperative risk factors in the event of a dural tear to guide prophylactic measures such as more aggressive and evidence-based anticoagulation therapy for patients at risk.

Brian A. Karamian, Tony Tannoury, Khoa S. Tran, Alexander R. Vaccaro

References

196. Yoshihara H, Yoneoka D. Incidental dural tear in cervical spine surgery: analysis of a nationwide database. *J Spinal Disord Tech*. 2015 Feb;28(1):19-24.
197. Takenaka S, Makino T, Sakai Y, Kashi M, Iwasaki M, Yoshikawa H, Kaito T. Dural tear is associated with an increased rate of other perioperative complications in primary lumbar spine surgery for degenerative diseases. *Medicine (Baltimore)*. 2019 Jan;98(1):e13970.
198. Wang JC, Bohlman HH, Riew KD. Dural tears secondary to operations on the lumbar spine. Management and results after a two-year-minimum follow-up of eighty-eight patients. *J Bone Joint Surg Am*. 1998 Dec;80(12):1728-32.
199. Alluri R, Kang HP, Bouz G, Wang J, Hah RJ. The True Effect of a Lumbar Dural Tear on Complications and Cost. *Spine (Phila Pa 1976)*. 2020 Feb 1;45(3):E155-62.
200. Durand WM, DePasse JM, Kuris EO, Yang J, Daniels AH. Late-presenting dural tear: incidence, risk factors, and associated complications. *Spine J*. 2018 Nov; 18(11):2043-50.
201. Kaplan D, Casper TC, Elliott CG, Men S, Pendleton RC, Kraiss LW, Weyrich AS, Grissom CK, Zimmerman GA, Rondina MT. VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock. *Chest*. 2015 Nov;148(5):1224-30.
202. Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH. Deep vein thrombosis and its prevention in critically ill adults. *Arch Intern Med*. 2001 May 28; 161(10):1268-79.
203. Cook D, Attia J, Weaver B, McDonald E, Meade M, Crowther M. Venous thromboembolic disease: an observational study in medical-surgical intensive care unit patients. *J Crit Care*. 2000 Dec;15(4):127-32.
204. Ribic C, Lim W, Cook D, Crowther M. Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review. *J Crit Care*. 2009 Jun;24(2):197-205.
205. Cammisia FP Jr, Girardi FP, Sangani PK, Parvataneni HK, Cadag S, Sandhu HS. Incidental durotomy in spine surgery. *Spine (Phila Pa 1976)*. 2000 Oct 15;25(20): 2663-7.
206. Eismont FJ, Wiesel SW, Rothman RH. Treatment of dural tears associated with spinal surgery. *J Bone Joint Surg Am*. 1981 Sep;63(7):1132-6.
207. Yang SD, Ding WY, Yang DL, Shen Y, Zhang YZ, Feng SQ, Zhao FD. Prevalence and Risk Factors of Deep Vein Thrombosis in Patients Undergoing Lumbar Interbody Fusion Surgery: A Single-Center Cross-Sectional Study. *Medicine (Baltimore)*. 2015 Dec;94(48):e2205.
208. Radcliff KE, Sidhu GD, Kepler CK, Gruskay J, Anderson DG, Hilibrand A, Albert TJ, Vaccaro AR. Complications of Flat Bedrest Following Incidental Dural Repair. *J Spinal Disord Tech*. 2012. Epub ahead of print.
209. Smorgick Y, Baker KC, Herkowitz H, Montgomery D, Badve SA, Bachison C, Erickson S, Fischgrund JS. Predisposing factors for dural tear in patients undergoing lumbar spine surgery. *J Neurosurg Spine*. 2015 May;22(5):483-6.
210. Weber C, Piek J, Gunawan D. Health care costs of incidental durotomies and postoperative cerebrospinal fluid leaks after elective spinal surgery. *Eur Spine J*. 2015 Sep;24(9):2065-8.
211. Jaffer AK, Barsoum WK, Krebs V, Hurbaneck JG, Morra N, Brotman DJ. Duration of anesthesia and venous thromboembolism after hip and knee arthroplasty. *Mayo Clin Proc*. 2005 Jun;80(6):732-8.
212. Xenos ES, Vargas HD, Davenport DL. Association of blood transfusion and venous thromboembolism after colorectal cancer resection. *Thromb Res*. 2012 May; 129(5):568-72.
213. Turpie AG, Chin BS, Lip GY. Venous thromboembolism: pathophysiology, clinical features, and prevention. *BMJ*. 2002 Oct 19;325(7369):887-90.

- 214.** Kroegel C, Reissig A. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. *Respiration*. 2003 Jan-Feb;70(1):7-30.
- 215.** Peterson, C.W. Venous Thrombosis: An Overview. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*. 1986, 6: 12S-17S. <https://doi.org/10.1002/j.1875-9114.1986.tb04025.x>
- 216.** Eppihimer MJ, Schaub RG. P-Selectin-dependent inhibition of thrombosis during venous stasis. *Arterioscler Thromb Vasc Biol*. 2000 Nov;20(11):2483-8.
- 217.** Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution. *Arterioscler Thromb Vasc Biol*. 2008 Mar;28(3):387-91.
- 218.** McLynn RP, Diaz-Collado PJ, Ottesen TD, Ondeck NT, Cui JJ, Bovonratwet P, Shultz BN, Grauer JN. Risk factors and pharmacologic prophylaxis for venous thromboembolism in elective spine surgery. *Spine J*. 2018 Jun;18(6):970-8.
- 219.** Inoue H, Watanabe H, Okami H, Kimura A, Takeshita K. The Rate of Venous Thromboembolism Before and After Spine Surgery as Determined with Indirect Multidetector CT. *JB JS Open Access*. 2018 Aug 15;3(3):e0015.
- 220.** Schoenfeld AJ, Herzog JP, Dunn JC, Bader JO, Belmont PJ Jr. Patient-based and surgical characteristics associated with the acute development of deep venous thrombosis and pulmonary embolism after spine surgery. *Spine (Phila Pa 1976)*. 2013 Oct 1;38(21):1892-8.
- 221.** Rogers SO Jr, Kilaru RK, Hosokawa P, Henderson WG, Zinner MJ, Khuri SF. Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: results from the patient safety in surgery study. *J Am Coll Surg*. 2007 Jun;204(6):1211-21.
- 222.** Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. *Ann Surg*. 2010 Feb;251(2):344-50.

12 - Should pediatric patients undergoing major spine procedures require routine VTE prophylaxis?

Response/Recommendation: Routine administration of pharmacologic venous thromboembolism (VTE) prophylaxis for major spinal procedures in pediatric patients is not supported by current evidence. Chemoprophylaxis should be limited to patients with multiple risk factors. Controversy exists on the utility of mechanical prophylaxis although poses minimal risk.

Strength of Recommendation: Limited.

Delegates vote: Agree 96.30% Disagree 3.57% Abstain 0.00% (Strong Consensus).

Rationale: Currently, there is no widely accepted guideline for VTE prophylaxis in pediatric orthopaedic patients and a majority of pediatric orthopaedic surgeons are unaware of their own institution's VTE prophylaxis protocol²²³. In a multi-national study on critically ill children, 17.6% of 2,484 patients met the criteria of the American College of Chest Physicians (ACCP) guidelines for pharmacologic prophylaxis, however, almost 2/3 of those patients did not receive prophylaxis due to lack of evidence²²⁴.

The incidence of VTE in pediatric orthopaedic patients primarily derives from three main existing registries (Canada, Germany, and the Netherlands) and is reported to be 5.3 per 10,000 hospital admissions and 0.7 per 100,000 children. Previously documented risk factors for VTE in pediatric patients include intubation, intensive care unit (ICU) admission, blood transfusion, major surgery, central venous catheter placement, and longer length of ICU stay²²⁵. The estimated incidence of VTE following spinal fusion in children is 0.21% and risk factors include adolescent children and children with diagnoses of congenital scoliosis, syndromic spinal deformities, kyphoscoliosis, or thoracolumbar fractures²²⁶. In a 28-year follow up study on pediatric scoliosis surgery, Erkilinc et al., found a lower extremity deep venous thrombosis (DVT) rate of 0.13% in 1,471 patients and zero patients were diagnosed with pulmonary embolism (PE)²²⁷.

There is a paucity of data on the utility of VTE prophylaxis in pediatric patients undergoing major spine procedures. However, due to the extremely low incidence of VTE in pediatric patients, no studies have identified a clear benefit thus far. In a retrospective review of 73 patients aged 14 - 19 undergoing posterior spinal fusion for adolescent idiopathic scoliosis (AIS), there were no DVT, or PE identified in any patients, regardless of whether chemoprophylaxis was used²²⁸. In a 2020, multi-center retrospective study, the incidence of VTE after elective spine and lower-extremity surgery in children with neuromuscular complex chronic conditions was 4 per 10,000, and only 4% used chemoprophylaxis. Moreover, only 10% used compression devices, raising the question whether mechanical prophylaxis should even be recommended in this cohort²²⁵. Asian literature also has shown that except for spinal cord injury patients the routine use of anticoagulation for spine surgery in children is not recommended¹²⁹⁻²³¹.

There is minimal research on potential complications of chemoprophylaxis in pediatric spinal patients. A 2019 study on VTE chemoprophylaxis in AIS patients showed a higher but statistically non-significant difference in post-operative drain output as well as the amount of wound oozing in patients who received post-operative chemoprophylaxis compared to those who didn't. Length of stay was significantly shorter in the non-chemoprophylaxis group. The authors did not find a correlation between when chemoprophylaxis was initiated and the reported complications²²⁸.

To evaluate standard of care among experts, forty-seven spine surgeons (orthopaedic spine surgeon and neurosurgeon) were surveyed on current trends in the perioperative administration of thromboprophylaxis in spinal surgery. Pharmacologic prophylaxis was used for spinal cord injury (SCI) by 91% of surgeons compared to 62% for non-SCI. Similar results were seen in anterior thoracolumbar procedures vs. posterior thoracolumbar surgeries. Almost half of the surgeons experienced complications with low-molecular-weight heparin (LMWH) including epidural hematomas, retropharyngeal hematoma, thrombocytopenia, and wound hematoma²³².


Harold A. Fogel, Ali Parsa, Stephen DiMaria

References

- 223.** Murphy RF, Williams D, Hogue GD, Spence DD, Epps H, Chambers HG, Shore BJ. Prophylaxis for pediatric venous thromboembolism: current status and changes across pediatric orthopaedic society of North America From 2011. *J Am Acad Orthop Surg*. 2020 May 1;28(9):388-94.
- 224.** Otten D. A Multinational Study of Thromboprophylaxis Practice in Critically Ill Children: Faustino E, Hanson S, Spinella P, et al *Crit Care Med* 2014; 42: 1232-40. *J Emerg Med*. 2014 Aug 1;47(2):258.
- 225.** Shore BJ, Hall M, Matheny TH, Snyder B, Trenor CC 3rd, Berry JG. Incidence of Pediatric Venous Thromboembolism After Elective Spine and Lower-Extremity Surgery in Children With Neuromuscular Complex Chronic Conditions: Do we Need Prophylaxis? *J Pediatr Orthop*. 2020 May/ Jun;40(5):e375-9.
- 226.** Jain A, Karas DJ, Skolasky RL, Sponseller PD. Thromboembolic complications in children after spinal fusion surgery. *Spine (Phila Pa 1976)*. 2014 Jul 15;39(16):1325-9.
- 227.** Erkilinc M, Clarke A, Poe-Kochert C, Thompson GH, Hardesty CK, O'Malley N, Mistovich RJ. Is there value in venous thromboembolism chemoprophylaxis after pediatric scoliosis surgery? A 28-year single center study. *J Pediatr Orthop*. 2021 Mar 1;41(3):138-42.
- 228.** Kochai A, Cicekli O, Bayam L, Türker M, Sariyilmaz K, Erkokmaz Ü. Is pharmacological anticoagulant prophylaxis necessary for adolescent idiopathic scoliosis surgery? *Medicine (Baltimore)*. 2019 Jul;98(29):e16552.

- 229.** Cheang MY, Yeo TT, Chou N, Lwin S, Ng ZX. Is anticoagulation for venous thromboembolism safe for Asian elective neurosurgical patients? A single centre study. *ANZ J Surg.* 2019 Jul;89(7-8):919-24.
- 230.** Do JG, Kim H, Sung DH. Incidence of deep vein thrombosis after spinal cord injury in Korean patients at acute rehabilitation unit. *J Korean Med Sci.* 2013 Sep;28(9):1382-7.
- 231.** Rathore MF, Hanif S, New PW, Butt AW, Aasi MH, Khan SU. The prevalence of deep vein thrombosis in a cohort of patients with spinal cord injury following the Pakistan earthquake of October 2005. *Spinal Cord.* 2008 Jul;46(7):523-6.
- 232.** Ploumis A, Ponnappan RK, Sarbello J, Dvorak M, Fehlings MG, Baron E, Anand N, Okonkwo DO, Patel A, Vaccaro AR. Thromboprophylaxis in traumatic and elective spinal surgery: analysis of questionnaire response and current practice of spine trauma surgeons. *Spine (Phila Pa 1976).* 2010 Feb 1;35(3):323-9.

Appendix

 Supporting material provided by the authors is posted with the online version of this article as a data supplement at [jbjs.org \(http://links.lww.com/JBJS/G864\)](http://links.lww.com/JBJS/G864).

Note: The ICM-VTE Spine Delegates includes Chadi Tannoury, MD, Boston University Medical Center, Boston, Massachusetts; Andrea Angelini, MD, Department of Orthopedics and Orthopedic Oncology, University of Padova, Padua, Italy; Jose A. Canseco, MD, Rothman Orthopaedic Institute, Philadelphia, Pennsylvania; Ana Castel-Oñate, MD, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Emanuele Chisari, MD, Rothman Orthopaedic Institute, Philadelphia, Pennsylvania; Adwin Denasty, MD, University of Rochester Medical Center, Rochester, New York; Stephen DiMaria, BS, Rothman Orthopaedic Institute, Philadelphia, Pennsylvania; Harold A. Fogel, MD, Harvard Medical School, Boston, Massachusetts; Jeremy L. Fogelson, MD, Mayo Clinic, Rochester, Minnesota; Graham S. Goh, MD, Rothman Orthopaedic Institute, Philadelphia, Pennsylvania; Jonathan N. Grauer, MD, Yale School of Medicine, New Haven, Connecticut; Olivier Q. Groot, MD, Massachusetts General Hospital, Boston, Massachusetts; Arun P. Kanhere, MD, Rothman Orthopaedic Institute, Philadelphia, Pennsylvania; Brian A. Karamian, MD, Rothman Orthopaedic Institute, Philadelphia, Pennsylvania; Gentaro Kumagai, MD, Department of Orthopaedic Surgery, Hirosaki University Graduate School of Medicine; Hirosaki, Japan; Mark Lambrechts, MD, Rothman Orthopaedic Institute, Philadelphia, Pennsylvania; Addisu Mesfin, MD, University of Rochester, Monroe County, New York; Ali Parsa, MD, Orthopedic Research Center, Department of Orthopedic Surgery, Mashhad University of Medical Sciences, Mashhad, Iran; Javad Parvizi, MD, FRCS, Rothman Orthopaedic Institute, Philadelphia, Pennsylvania; David W. Polly Jr., MD, University of Minnesota, Minneapolis, Minnesota; Camilo Restrepo, MD, Rothman Orthopaedic Institute, Philadelphia, Pennsylvania; Joseph H. Schwab, MD, Harvard Medical School, Boston, Massachusetts; Nicholas M. Siegel, MD, Rothman Orthopaedic Institute, Philadelphia, Pennsylvania; Ryan M. Sutton, MD, Rothman Orthopaedic Institute, Philadelphia, Pennsylvania; Tony Tannoury, MD, Boston University, Boston, Massachusetts; Gregory R. Toci, MD, Rothman Orthopaedic Institute, Philadelphia, Pennsylvania; Khoa S. Tran, MD, Rothman Orthopaedic Institute, Philadelphia, Pennsylvania; Alexander R. Vaccaro, MD, Rothman Orthopaedic Institute, Philadelphia, Pennsylvania.